WO2003037372A1 - Method for restoring disordered physiological processes and a medicament for carrying out said method - Google Patents

Method for restoring disordered physiological processes and a medicament for carrying out said method Download PDF

Info

Publication number
WO2003037372A1
WO2003037372A1 PCT/RU2002/000377 RU0200377W WO03037372A1 WO 2003037372 A1 WO2003037372 A1 WO 2003037372A1 RU 0200377 W RU0200377 W RU 0200377W WO 03037372 A1 WO03037372 A1 WO 03037372A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibodies
items
medicinal product
days
patient
Prior art date
Application number
PCT/RU2002/000377
Other languages
French (fr)
Russian (ru)
Inventor
Oleg Iliich Epshtein
Tamara Mikhailovna Kolyadko
Mark Borisovich Shtark
Original Assignee
Oleg Iliich Epshtein
Tamara Mikhailovna Kolyadko
Mark Borisovich Shtark
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2001129325/14A external-priority patent/RU2001129325A/en
Application filed by Oleg Iliich Epshtein, Tamara Mikhailovna Kolyadko, Mark Borisovich Shtark filed Critical Oleg Iliich Epshtein
Publication of WO2003037372A1 publication Critical patent/WO2003037372A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum

Definitions

  • Iz ⁇ b ⁇ e ⁇ enie ⁇ n ⁇ si ⁇ sya ⁇ ⁇ blas ⁇ i medicine and m ⁇ zhe ⁇ by ⁇ is ⁇ lz ⁇ van ⁇ to treat ⁇ a ⁇ l ⁇ giches ⁇ i ⁇ Sind ⁇ m ⁇ v, ⁇ busl ⁇ vlenny ⁇ or s ⁇ v ⁇ zhdayuschi ⁇ sya na ⁇ usheniem ⁇ egulyatsii ⁇ lyuchevy ⁇ ⁇ izi ⁇ l ⁇ giches ⁇ i ⁇ ⁇ tsess ⁇ v - mezh ⁇ le ⁇ chny ⁇ vzaim ⁇ deys ⁇ vy, ⁇ li ⁇ e ⁇ atsii and di ⁇ e ⁇ entsi ⁇ v ⁇ i ⁇ le ⁇ .
  • the invention is aimed at improving the efficacy and safety of treating diseases caused by the violation of physiological processes
  • SIGNIFICANT FOX (DR. 26) 2 ⁇ eguli ⁇ uemy ⁇ tsi ⁇ inami and ⁇ un ⁇ tsi ⁇ naln ⁇ ⁇ d ⁇ bnymi them bel ⁇ ami and ⁇ e ⁇ idami, ⁇ e v ⁇ lyuchal ⁇ would not ⁇ davlenie (bl ⁇ i ⁇ vanie) and m ⁇ di ⁇ i ⁇ atsiyu bi ⁇ l ⁇ giches ⁇ y a ⁇ ivn ⁇ s ⁇ i tsi ⁇ in ⁇ v or ⁇ un ⁇ tsi ⁇ naln ⁇ ⁇ d ⁇ bny ⁇ them ⁇ egulya ⁇ v u ⁇ azanny ⁇ ⁇ tsess ⁇ v;
  • the invention is also directed to the creation of a new medicinal product that does not have any expressed effect.
  • the medicinal product has an active form of overdose which is very small or small, immune or natural, or is immune to health or is immune.
  • an active form of an antibody for a single or a small amount of an antifreeze or a mixture of an amount of at least
  • the medicinal product is prepared by the following method.
  • cytokines By biological methods, these cytokines, squirrels, or peptides are consumed and one or several of them are selected.
  • ⁇ further ⁇ azhdy izb ⁇ anny bel ⁇ , ⁇ e ⁇ id or eg ⁇ ⁇ agmen ⁇ (at least 3 amin ⁇ isl ⁇ nzh ⁇ s ⁇ a ⁇ v) is ⁇ lzuyu ⁇ in ⁇ aches ⁇ ve immun ⁇ gena for immunization lab ⁇ a ⁇ nzh zhiv ⁇ ny ⁇ and ⁇ lucheniya ⁇ li ⁇ l ⁇ nalnzh immunnzh an ⁇ i ⁇ el, or gib ⁇ id ⁇ mn ⁇ y ⁇ e ⁇ n ⁇ l ⁇ gii for ⁇ lucheniya m ⁇ n ⁇ l ⁇ nalnzh an ⁇ i ⁇ el. Obtained antibodies are cleared by the method of an affirmative process.
  • the current processing in the process of deducing the concentration is also possible to carry out ultrasound, electric or other physical interference.
  • Example 2 Patient U., 34 years old, for 10 years, it suffers from a mild moderate course, complicated by an arrhythmic arthritis.
  • the symptoms of the disease are assigned to: a generic antibody for the patient 10 - in the case of a dilution of 2 patients.
  • the manifestation of new plaques was improved, the general condition improved, the symptoms of arthritis disappeared; after 10 days after the start of treatment - an apparent regression of all the general plaques, the remission of the disease is reached. It is recommended that you take a drug.
  • Example Z When an experimental study of the efficacy of overdose of interleukin 13 (IL-13) was performed, an analgesic increase was sensitized (sensitized). For this test, with a weight of 300 g, they were sensitized by the intramuscular injection of 0.5 ml of a physiological solution containing valbumin in a dose of 20 mg and 100 mg of aluminum hydroxide. After 3 weeks after sensitization, an anaphylactic reaction ( ⁇ ) was caused by a discontinuing dose of valbumin, which was administered as an aerosol within 60 minutes (0.5% in 0.9%).
  • IL-13 interleukin 13
  • the large cross-border antibodies for the IL-13 group (a mixture of the C12 + C30 + C200 homogeneous dilutions) were administered at a daily interval of 0.5 ml.
  • the on-site group entered the distilled water.
  • Example 4 The ability to over-tighten the body of an antibody to an interleukin 12 (IL-12) stimulates the inactivity by reducing the inconvenience of the decrease
  • Generated tuberculosis was simulated by introducing vascular tissue at a rate of 0.5 in vascular infusion to the male inferior males.
  • On-line antibodies for the IL-12 fragment (a mixture of homogenous dilutions C6, C1000) were injected with a dose of 0.2 ml of an intruder for 2 days. The on-site group entered the distilled water. Treatment was started after infection development (on day 4).
  • EXAMPLE 5 In mice of the C obedient line (18-22g), the systemic condition was simulated by introducing an internal perfusion in a group of 0.1 ml. Further m ⁇ i ⁇ y ⁇ n ⁇ y g ⁇ u ⁇ y ⁇ az 1 to 3 chasa ⁇ luchali ⁇ e ⁇ aln ⁇ ⁇ 0.2 ml m ⁇ n ⁇ l ⁇ nalny ⁇ an ⁇ i ⁇ el in ⁇ e ⁇ ley ⁇ inu ⁇ 1 and ⁇ ⁇ li ⁇ l ⁇ nalny ⁇ an ⁇ i ⁇ el ⁇ a ⁇ u ne ⁇ za ⁇ u ⁇ li al ⁇ a, ⁇ azhdy an ⁇ i ⁇ el view - in a mixture g ⁇ me ⁇ a ⁇ iches ⁇ i ⁇ ⁇ azvedeny C6 + C30 + C200. Our business team received distilled water. When evaluating the survival rate, it was found that in the experimental group the lethality was 36% ”, having only 100% in the economy; The death of livestock occurred
  • Example 6 Patient L., 49 years old, complained of increased fatigue, fatigue, pain and decreased mobility. Diagnosis: "A simple two-sided distress.” Designated by the industrial division of the Mono-National Antibody 1 in the home breeding C50 ⁇ 10
  • SIGNIFICANT FOX (DR. 26) 8 drops per ⁇ 3 or 3 times per day. After a week, physical activity and pain relief were noted.
  • Example 7 Patient,., 56 years old, had been treated for non-operative inoculations with complaints of cough, increased pain. An investigation revealed an increase in body temperature up to 37.5 ° ⁇ .
  • ⁇ aznachenie ⁇ entsi ⁇ vann ⁇ g ⁇ ⁇ as ⁇ v ⁇ a m ⁇ n ⁇ l ⁇ nalnzh an ⁇ i ⁇ el ⁇ an ⁇ ag ⁇ nis ⁇ u ⁇ etse ⁇ a in ⁇ e ⁇ ley ⁇ ina 1 g ⁇ me ⁇ a ⁇ iches ⁇ m ⁇ azvedenii C50 ⁇ 15 ⁇ a ⁇ el 3 ⁇ aza day ⁇ zv ⁇ lil ⁇ n ⁇ maliz ⁇ va ⁇ ⁇ em ⁇ e ⁇ a ⁇ u ⁇ u and us ⁇ ani ⁇ ⁇ ashel che ⁇ ez ⁇ sle 4 days of treatment.
  • EXAMPLE 8 Overhead lines of C57 line were injected with 0.1 ml of a complex of antibodies to intuleukin 2 in the home breeding of C ⁇ . The separation of the indicators of the immune system after 7 days of the introduction of the drug revealed an increase in the stimulation of stimulation by 30%.
  • Example 9 Patient Sh., 48 years old, treated with complaints of heartbeat, weakness, asthma. An examination revealed iron deficiency anemia, a decrease in the level of hemoglobin up to 70 g / l. Diet and food was assigned to a multi-functional antibody for Interaleukin 3 in a home breeding of C200 1 teaspoon 3 times a day. After 2 weeks of regression, the stated complaints were ascertained, the level of hemoglobin increased to 110 g / l.
  • SIGNIFICANT FOX 9 Acceptance of endothelial cells of expression of ⁇ -1 adhesion molecules by 20% after 48 hours of incubation.
  • Example 11 Patient ⁇ ., 7 years old, was consulted in connection with complaints of sickness, absenteeism, pain, and illness. The investigation revealed eosinophilia caused by ascaridosis.
  • ⁇ aznachenie ⁇ vechi ⁇ ⁇ li ⁇ l ⁇ nalny ⁇ an ⁇ i ⁇ el ⁇ in ⁇ e ⁇ ley ⁇ inu 5 in admixture g ⁇ me ⁇ a ⁇ iches ⁇ i ⁇ ⁇ azvedeny C12 + C30 + C200 ⁇ 1 chayn ⁇ y l ⁇ zh ⁇ e 3 ⁇ aza day ⁇ zv ⁇ lil ⁇ us ⁇ ani ⁇ u ⁇ azannye zhal ⁇ by che ⁇ ez 4 days treatment 10 days treatment che ⁇ ez ⁇ d ⁇ ve ⁇ zhden ⁇ ⁇ su ⁇ s ⁇ vie gelmin ⁇ za and e ⁇ zin ⁇ ilii.
  • Example 12 Patient D., 65 years old, treated with complaints of pain in the back. In the course of the investigation, an outbreak of an obstructive lumbar obstruction was revealed. Potentially distributed equipment is assigned to the intaleukin 6 in a home dilution of C200 200 1 tablet 3 times a day. After 5 days of the onset of disease, the elimination of the pain syndrome is detected.
  • EXAMPLE 14 An experiment has been made to evaluate the effect of reducing active antibody intake on intuleukin 8 on the development of inflammation in the living room. For 7 days, a test group received an oral preparation of 0.5 ml of a small-scale anti-IL-8 antibody diluted in a C100 homogenous dilution. Accounting
  • SIGNIFICANT FOX (DR. 26) 10 differences in the mass of extremities in the commercial and experimental groups revealed a 2–7-day decrease in the total reaction by the action of the drug by 35%.
  • Example 15 Patient C, 36 years old, was treated with pallinosis. It is designated as an integral mono-antibody for intereleukin 9 in the form of a solution in the Homophilic dilution C50 ⁇ 5 5, the droplet is intranasal 2 times a day. After 5 days of illness, the symptoms of allergies are eliminated.
  • Example 16 Patient ⁇ ., 58 years old, suffering from ischemic heart disease, was treated with complaints of pain in the area of the heart and insufficient stress. It is offered by a multi-ethnic antibody for 10 diluted home-breeding C ⁇ , for 1 table 3 times a day. After 3 days, the patient noted a decrease in the severity of the pain syndrome. Recommend a cure for treatment.
  • Example 17 Patient D., 64 years old, treated with complaints of pain, cyanosis, and low-grade infrequency. In the course of the examination, a diagnosis of a deep vein of burning was diagnosed on the basis of an increase in the content of the heart in the front. It is recommended for use with antibodies to interleukin 11 in a mixture of Homophilus dilutions ⁇ b + Sz ⁇ + Syu ⁇ 1 teaspoon 3 times a day. After 7 days, it was found that the complaint was fixed, the number of cases was normalized.
  • Example 18 For children with small-breast cancer, induced by benzene, they injected 0.5 ml of an intensive-care drug in the Republic of Belarus. It has been established that the 30-day introduction of the drug reduces the size and quantity of pulses by 40%, increases the life span of life, and also increases
  • SIGNIFICANT FOX (DR. 26) 11 practical activity with a cell, which is at the core of an experimental group.
  • mice of the C57 ⁇ line were installed, that the introduction of an external injury prevents a person from suffering from thrombocytopenia.
  • Conditions of administration at a dose of 0.1 ml in a diluted C200 dilution daily for 7 days.
  • Example 23 The incubation of fractions of the skin of a human being is 0.5% of the share of the investment in the inlet of the inlet of the 120-year-old inlet
  • Example 26 A person who was affected by an alter- native virus caused an increase in the level of internal disturbance in a case of incidence of miscarriage of interest.
  • Example 27 Patient ⁇ ., 56 years old, treated with complaints of painful rash on the lips and other faces, resulting in a burning pain and an increase in temperature. Diagnosed with herpes infection and recommended
  • Example 28 Patient U., 24 years of age, being at the 7th month of pregnancy, is socialized due to a late pregnancy. Designation
  • SIGNIFICANT FOX 13 ⁇ entsi ⁇ vann ⁇ g ⁇ ⁇ as ⁇ v ⁇ a m ⁇ n ⁇ l ⁇ nalnzh an ⁇ i ⁇ el an ⁇ i ⁇ el ⁇ -in ⁇ e ⁇ e ⁇ nu ⁇ au (G ⁇ - ⁇ ai) in g ⁇ me ⁇ a ⁇ iches ⁇ m ⁇ azvedenii C200 ⁇ zv ⁇ lil ⁇ us ⁇ ani ⁇ ⁇ e ⁇ i, and gi ⁇ e ⁇ enziyu ⁇ izna ⁇ i ⁇ e ⁇ - ⁇ latsen ⁇ a ⁇ n ⁇ y ned ⁇ s ⁇ a ⁇ chn ⁇ s ⁇ i che ⁇ ez 7 days ⁇ iema ⁇ 10 ⁇ a ⁇ el 3 ⁇ aza per day.
  • mice with antibodies to ⁇ caused a substantial (2.3-fold) decrease in the number of metastatic nodes in the lungs, and the inhibition rate of metastasis was 73%.
  • Example 30 Patient ⁇ ., 58 years old, treated with complaints of pain in his lower joints, and their breathing and decreased mobility. As a result of the investigation, a diagnosis of “reactive arthritis” was made. The designation of the unit is mono-local
  • EXAMPLE 32 Patient ⁇ ., 28 years old, received a cure for treatment of a newly acquired immunodeficiency syndrome, which is present in the presence of a sarcoma disease.
  • ⁇ aznachenie ⁇ e ⁇ a ⁇ a ⁇ a m ⁇ n ⁇ l ⁇ nalnzh an ⁇ i ⁇ el ⁇ ley ⁇ zingibi ⁇ uyuschemu ⁇ a ⁇ u (LI ⁇ ) in a mixture g ⁇ me ⁇ a ⁇ iches ⁇ i ⁇ ⁇ azvedeny C12 + C200 + SYU00 ⁇ 1 ⁇ able ⁇ e 3 ⁇ aza day vyzval ⁇ ⁇ eg ⁇ ess ⁇ u ⁇ li, uluchshil ⁇ ⁇ bschee sam ⁇ chuvs ⁇ vie ⁇ atsien ⁇ a che ⁇ ez ⁇ sle 14 days of treatment.
  • Example 33 Patient ⁇ ., 30 years old, was discharged to the department of hematology with a diagnosis of autoimmune agranulocytosis, the content of leukemia in the patient on 9 October.
  • Example 34 Patient L., 67 years old, treated with complaints of easy healing and expulsion in the area of second-degree burns,
  • SIGNIFICANT FOX (DR. 26) 15 cases in 2 weeks prior to visit. Designated by the manufacturer of antibodies ⁇ ⁇ - ⁇
  • P ⁇ ime ⁇ 35 is ⁇ lz ⁇ vaniem e ⁇ s ⁇ e ⁇ imen ⁇ aln ⁇ y m ⁇ deli se ⁇ iches ⁇ g ⁇ v ⁇ s ⁇ aleniya at ⁇ ys, vyzvann ⁇ g ⁇ ⁇ d ⁇ zhnym introduction ⁇ ul ⁇ u ⁇ y ⁇ aigeiz ( ⁇ YU 90) ⁇ azan ⁇ presence bi ⁇ l ⁇ giches ⁇ y a ⁇ ivn ⁇ s ⁇ i at sve ⁇ malzh d ⁇ z an ⁇ i ⁇ el ⁇ T- ⁇ S ⁇ (g ⁇ anul ⁇ tsi ⁇ a ⁇ ny ⁇ l ⁇ nies ⁇ imuli ⁇ uyuschy ⁇ a ⁇ ).
  • Antibodies in the Homo dilution SJ00 introduced a direct dose of 0.3 ml for 5 days. ⁇ The experimental group of livelihoods showed a marked decrease in lethality (by 3 times), a significant decrease in mute-septic phenomena in the incidence of increased incidence of physical and physical activity.
  • SIGNIFICANT FOX (DR. 26) 16 mkg / kg.
  • ⁇ ysy ⁇ y ⁇ n ⁇ y g ⁇ u ⁇ y ⁇ sle administration tse ⁇ ulina ⁇ luchali a ⁇ ivi ⁇ vannye sve ⁇ malye d ⁇ zy ⁇ li ⁇ l ⁇ nalysh ⁇ ⁇ lichi ⁇ an ⁇ i ⁇ el ⁇ ⁇ em ⁇ inu S ⁇ S (su ⁇ k ⁇ e- ⁇ ise ⁇ ⁇ eigg ⁇ Y ⁇ set ⁇ a ⁇ gas ⁇ a ⁇ ) (an ⁇ i-S ⁇ S) - mixture g ⁇ me ⁇ a ⁇ iches ⁇ i ⁇ ⁇ azvedeny C12 SZ ⁇ , C200 - in v ⁇ dn ⁇ m ⁇ as ⁇ v ⁇ e as sv ⁇ b ⁇ dn ⁇ g ⁇ d ⁇ s ⁇ u ⁇ a in ⁇ e ⁇ vye su ⁇ i and then at 0.2 ml 1 time per day.
  • the kruppy kruppy krysys received the distilled water.
  • the severity of ⁇ P was assessed, separating the level of plasma amylase and moderate changes in the pancreas (the degree of failure of the acinus cells, the degree of intensity was intense).
  • the severity of the VAS was determined by measuring the incidence of mycosis of the lungs and the activity of myelopexydase.
  • ⁇ yyavlen ⁇ , ch ⁇ at ⁇ ys, ⁇ luchavshi ⁇ an ⁇ i ⁇ ela ⁇ S ⁇ S, che ⁇ ez 1 su ⁇ i ⁇ sle administration tse ⁇ ulina d ⁇ s ⁇ ve ⁇ n ⁇ below were u ⁇ ven amylase syv ⁇ i (1.8 ⁇ aza) s ⁇ e ⁇ en ne ⁇ za ⁇ le ⁇ atsinus ⁇ v (3 ⁇ aza) s ⁇ e ⁇ en ⁇ e ⁇ a ⁇ a ⁇ en ⁇ imy (2.3 ⁇ aza) vy ⁇ azhenn ⁇ s ⁇ v ⁇ s ⁇ ali ⁇ eln ⁇ y pancreatic fluid infiltration (2.5 times) than in the control.
  • the introduction of the drug also led to a decrease in the activity of myeloepoxidase (by 1.8 times) and a decrease in the incidence of lung vessels (by 3 times).
  • Example 38 Patient ⁇ ., 22 years old, was treated by a doctor with severe allergic disease (food allergy), a standard treatment. Appointed: mono-local antibodies to ectaxinum - a mixture of homogeneous dilutions ⁇ 12 + ⁇ 30 + ⁇ , only 1 tablet 2 times a day. On the 3rd day of treatment, the patient noticed a significant reduction in skin pruritus, normalization of sleep; After 7 days after the start of treatment, skin rash and itching were completely regressed. It is recommended that you take a drug. History of 6 months: recurrence of dermatitis was not great, despite non-compliance with strict children.
  • Example 40 Patient ⁇ ., 45 years old, treated with complaints of minor vesicular rashes and itching of the skin after an insult. Diagnosed with ⁇ papivnitsa. It is assigned a mnogonalnyh antibodies ⁇ ⁇ (a single chemically active factor) in a mixture of homogenous dilutions of C6 + C30 + C200 for 1 day. After 2 ⁇ days of illness, itching and hematomas were noted.
  • Example 41 Patient ⁇ ., 43 ⁇ years old, had complained of numerous complaints in the ambulatory region. It is designated as a pre-empted food solution for an antibody with a diluted dilution of C30 at 1 tea day on a 3-day basis. After 3 days after the start of treatment, a registered decrease in the number and size of the facilities has been registered.
  • Example 42 Patient ⁇ ., 48 years old, was treated by a patient for obstructive lumbar obstruction. ⁇ aznachen ⁇ e ⁇ alny ⁇ iem m ⁇ n ⁇ l ⁇ nalnzh an ⁇ i ⁇ el ⁇ ⁇ em ⁇ inu (Zh ⁇ in g ⁇ me ⁇ a ⁇ iches ⁇ m ⁇ azvedenii C200 ( ⁇ luchenn ⁇ m ⁇ i ⁇ m ⁇ schi ⁇ b ⁇ ab ⁇ i zvu ⁇ vym gene ⁇ a ⁇ m ⁇ i 20 Hz), ⁇ 5 ⁇ a ⁇ el 3 ⁇ aza per day. Che ⁇ ez 3 days of starting treatment ⁇ sle za ⁇ egis ⁇ i ⁇ van ⁇ us ⁇ anenie b ⁇ lev ⁇ g ⁇ Sind ⁇ ma.
  • Example 43 Patient ⁇ ., 32 radia, was treated with complaints of pain in the lower abdomen and an increase in body temperature that had occurred after cooling. ⁇
  • SIGNIFICANT FOX (DR. 26) 18 history of adnexitis, an unhealthy process in the external area. It is designated for industrial use of mono-analgesic antibodies ⁇ -c- ⁇ -c- ⁇ -chemokine C ⁇ in a homogeneous dilution of C6 ⁇ 10 kapel at a rate of 5 times a day. After 3 days of the onset of regression, the elimination of the pain syndrome and normalization of the body temperature.
  • Example 45 Patient L., 15 years old, handled complaints of dry, itchy rashes in the area of ankle bending and neck. According to the results of the investigation, a diagnosis of “neurology” was made. It is designated as a simple overdose to a multiple of antibodies to a pediatric dilution of C200 dilution of 1 table 2 times in a day. After 5 days of treatment, the itching and skin problems were registered.
  • Example 46 Patient G., 28 years old, treated with complaints of persistent pain in the lower jaw, which increased after cooling, and increased temperature. In the course of the investigation, the diagnosis was diagnosed: neuralgia is traditional. The appointment of a small-scale antibody to the Khemokin ⁇ fie-1 in a homogeneous dilution of ⁇ 50 takes 1 time 3 times a day, eliminates the need to take the test off.
  • Example 47 Cells of mice of the C57 ⁇ line were incubated with 0.1% of a small-scale antibody for ⁇ -chemotherapeutic dilution of ⁇ . When adding an intubation with antibodies ⁇ carlets for melanoma cells ⁇ 16 (at a rate of 10: 1), it was found that it was inconvenient
  • Example 48 ⁇ The experiment on the rifle with an overexposure (Eruli's test) is shown to protect the patient from an anomalous rate. ⁇ A group of lively animals who had received a direct oral administration of a potential antibody in the homosexual dilution of SJU 0.1 ml per 30 days experienced a 30% increase in life.
  • Example 49 Patient L., 31 years old, was treated with migraine, a resistant treatment for conventional treatment.
  • the drug is recommended for use with a comorbid-activating agent (a mixture of H20 dilutions C12 + C30 + C200), 1 tablet daily.
  • a comorbid-activating agent a mixture of H20 dilutions C12 + C30 + C200
  • 1 tablet daily for 3 weeks of the onset of the drug, there was no registered migraine. Recommend a cure for treatment.
  • Example 50 Patient ⁇ ., 47 years old, dealt with complaints of mild headaches and heaviness in the heart. In the course of the investigation, an increase in arterial pressure up to 160/90 mm was detected. Diagnosed with a chronic illness of 2 degrees. It is proposed to use a potentiated antibody for Chemokine 5 ⁇ in a home dilution of C200 10 10 drops 3 times a day and daily measurement ⁇ D. After 2 weeks, a stable normalization of the arterial pressure is noted.
  • Example 52 The experiment simulated an autoimmune panic in mice of the C57 ⁇ 1 line, for which the mice were given an internal interval with an interval of 1 hour / week.
  • the on-line group received the distilled water.
  • the pancreatic test index (GCF) was calculated as the ratio of gland weight / mouse weight;
  • GCF pancreatic test index
  • SIGNIFICANT FOX 21 degree of failure of the acinus cell, degree of the process of inflammation, the incidence of extensive pancreatic infiltration was lower than in the case of the card.
  • the TITR of the auto-counter in the panel was 1:64, in mice that received the anti- ⁇ -61, - 1: 4.
  • Example 53 A sick man, 46 years old, was allowed to go to a business unit for a scheduled emergency transaction. It has been identified that there is a tendency for patients to have health problems after they have been treated.
  • EXAMPLE 54 Patient C., 27 years old, was treated with a nesting alopecia for the last 3 months. Appointed: active small doses of a small antibody for the transfusion factor of the beta 2 person - a mixture of the dilution, 1 dilution. After a second appearance after 2 weeks: the restoration of the alopecia was stopped, the restoration of the hair began. A month after the start of treatment: there are no signs of alopecia.
  • Example 55 Patient G., 54 years old, treated with complaints of cough, a low-grade temperature treatment during the course of 3 weeks after the transferred group. In the course of the investigation, the presence of a secondary immunodeficiency was established (lymphopenia, decreased immunoglobulins in the serum). It is designated for industrial use of antibodies to the transformed factor of ⁇ in a diluted C200 dilution of 10 drops at a rate of 3 times per day. After 5 days, normalization of the temperature and the elimination of cough were noted; after 10 days, normalization of the indicators was detected.
  • EXAMPLE 56 An experiment in the field of at-risk skin of people is shown to be good, and at-risk patients are at risk of being at risk of having A 0.1% hostile animal in the C30 breeding was introduced into the 96 well plate of the hole containing the cellar. After 24 hours, 3 ⁇ -leucine was added to the cells. The results were taken into account with the inclusion of a radioactive label for 4 hours of incubation. Installed stimulation of the inclusion of the label by the action of the preparation of antibodies by 35%.
  • Example 57 Patient ⁇ ., 59 years old, was treated with compensated insulin-dependent diabetes mellitus. It is proposed for use with antibodies to an insulin-friendly compound (HF) in a diluted C200 dilution of 1 tablet 3 times a day. After 2 days, a decrease in the severity of clinical symptoms of hyperglycemia was registered, after 7 days - a steady normalization of glycemia, an increase in tolerance to physical symptoms.
  • HF insulin-friendly compound
  • Example 58 When studying the effect of active overdose on the basis of antibodies to insulin-like factor 1 (phase 1) on the course of ischemic stroke, there is a slight increase in ischemia
  • SIGNIFICANT FOX (DR. 26) 23 median cerebral artery therapy with general anesthesia.
  • the all-round antibodies to the Fragment 1 type (a mixture of C200 + CU00 dilutions) introduced a daily dose of 0.4 ml per day. during the day, the 2nd group - daily for 30 days.
  • Example 59 Patient L., 54 years of age, was treated with complaints of pain in the lower back and a decrease in the sensitivity of the outbreak of illness. ⁇ history - osteoarthritis, radicular syndrome. The appointment of an antibody combination to the incidence of miscarriage in a homosexual dilution of SJ00 at 1 time of 3 times a day was favorable to an increase in the likelihood of 5 days
  • Example 60 Patient ⁇ ., 48 years old, treated with complaints of increased frequency of onset of bronchial asthma and a decrease in the effectiveness of medical treatment. Assigned to a potential-based multi-channel anti-theft system ⁇
  • SIGNIFICANT FOX 24 factories of breeding in the home breeding C200 at 1 teaspoon 3 times a day. A registered decrease in the intensity and frequency of operations after 3 days of reception.
  • Example 61 Patient ⁇ ., 71 years old, suffering from non-insulin-dependent diabetes mellitus, was treated with complaints of an ulcer in the lower part of the stomach that did not heal for 2 weeks. Diagnosed with a “peptic ulcer”. Assigned to a meal with a potentiated component of an antibody for an epidemic in the city divorce on 10 October. After a week, ulcer healing is registered.
  • Example 62 Patient P., 62 years old, was treated with relapsing two-stage erosion of the disease on the basis of diabetes mellitus type 2. Treatment for 3 months with drugs that stimulate regeneration (salt, actevin, and degeneration) did not produce an expressed effect. Appointment: casualties for epidemiological treatment of a human patient (a mixture of homogeneous dilutions of C30 + C200 + CU00) - 1 treatment is required for 2 patients After the onset of manifestation after 7 days, a decrease in the area of erosion by 2 times was revealed, after 4 weeks after the start of treatment of erosion, the patient was completely epithelized.
  • Example 63 Application to the conjunctiva of the eye at a daily rate of 0.1 ml of a dilution of an antibody for the treatment of worsening of the medication
  • SIGNIFICANT FOX (DR. 26) 25, the ocular fundus is undergoing: an effective retinopathy, a significant number of new vessels, and multiple foci of accidents.
  • Example 65 Patient W., 27 years old, treated with complaints of weakness, headache, nausea, tinnitus. During the investigation, a decrease in the arterial pressure up to 90/60 mm. ⁇ .st. Diagnosed with vegetative-vascular distress. It is designated as a direct access unit for the installation of an industrial unit for industrial use (gas supply unit, gas supply, gas supply, gas supply, gas After 2 days of illness, normalization of arterial pressure and improvement of well-being are registered.
  • an industrial unit for industrial use gas supply unit, gas supply, gas supply, gas supply, gas supply, gas After 2 days of illness, normalization of arterial pressure and improvement of well-being are registered.
  • Example 66 In the experiment, the C57 etti ⁇ line mice introduced an increase in the potential for the incidence of the patient’s neglect of the patient. There was a significant increase in the content of carcass in the large brain (by 20%), as well as in weight and carnus of the thymus by 30%.
  • Example 67 Patient ⁇ ., 57 years old, has a long-term history of deterioration of the chronic ⁇ , has been hospitalized due to the growing liver failure. Appointed: multiple antibodies to the growth factor of a herbal mixture in a mixture of herbal dilutions C12 + C30 + C200 1 tablet 3 times a day. After 5 days after the start of treatment, the general condition improved
  • SIGNIFICANT FOX (DR. 26) 26 patients, the clinical and laboratory parameters of the liver were depleted, the level of bilirubin in the blood decreased.
  • EXAMPLE 68 Patient D., 42 years old, suffering from chronic tonsillitis, was treated due to physical pain in the area, due to the temperature of the body. The designation of a wide range of other antibodies to Interleukin 2 in the home breeding of C200 at 1 table 1 at 3 o'clock has eliminated the neglect of the day.
  • Example 69 The experiment on suspensions of the spleen carcasses of C57 ⁇ 1 is shown, which means that the incubation medium contains 0.2%, which is low sho ⁇ esi ⁇ ag ⁇ se ⁇ Gastog, L ⁇ - ⁇ ) in the C12 home breeding promotes stimulation of the active activity of the sediments by 20% after 24 hours of incubation.
  • Example 70 In the context of incubation of the culture of human skin, an infected virus infection, they contributed 1% of the incidence of the disease. It has been found that the release of the antibody causes a reduction in the performance of the culture system by 30% after 24 hours of incubation.
  • Example 73 Patient 3., 51 years old, suffering from chronic obstruction, was treated for a complaint of a muscular distress, and there was a greater risk of pain. Assigned
  • interleukin 1 ⁇ in addition to the commercial mono-antibody, it is suitable for interleukin 1 ⁇ in a diluted dilution of C300 ⁇ 10 droplet 2 times a day. After 2 days after the start of treatment, it was noted that pain and dysuria were relieved.
  • Example 74 Patient ⁇ ., 25 years old, treated with complaints of headaches, cough, elevated temperature. An examination revealed a hypothermia of 38 ° C.
  • Example 75 Patient ⁇ ., 46 years old, suffering from a peptic ulcer of a twelve-year old bowel, complicated complications of the patient, and has had an increase in obesity Served with a small portion of a poultry in a homosexual dilution of a bambesin in a home-grown dilution of C200 for 1 meal in 30 minutes before eating. After 3 days, it is noted that these symptoms have been removed.
  • Example 78 Patient ⁇ ., 11 years old, was advised on a daily basis for enuresis. There is a separate meal for a vasopressin in a homosexual dilution of C200 for 1 night test. For 3 weeks of observation, the incontinence is not detected.
  • Example 79 Patient S., 54 years old, suffering from a disease, was treated by the treatment of the disease. The preparation was assigned a small antibody for an epidemic inhibitor ( ⁇ ) in a dilution of C200 for 3 days. After 3 days, the accessory was bought, after 7, it was completely calculated that there were no other plaques.
  • ⁇ epidemic inhibitor
  • Example 80 Patient L., 34 years old, was treated with complaints of itching in the nose, reading, and fluid sore throat. Diagnosed with vasomotory rhinitis. It is recommended for use with a dilution of antibodies to a bradikinin in a home breeding of C30 at 1 tablet 3 times a day. After 2 days, the symptoms of vasomotor rhinitis have been removed.
  • Example 81 Patient ⁇ ., 34 ⁇ years old, treated with complaints of weakness, headache, fainting, taste distortion. ⁇ a history of 3 wares, royalties. An examination revealed a decrease in hemoglobin up to 80 g / l. The assignment of a small antibody to an eritrophotetin in a home breeding of C24 at 1 teaspoonful of meals resulted in an increase of 3 days per day, which increased the time of the day. After 20 days after the start of treatment, the level of hemoglobin increased to 120 g / l.
  • Example 82 Patient ⁇ ., 54 ⁇ years old, had complained of multiple abnormalities. In the course of the investigation, a thrombosis was detected. Designated with a rimpie of mono-mono-antibodies in the form of a diluted C200 dilution of 1 tablet 3 times a day. After 7 days of recurrence, hematomas were detected.
  • Example 84 Bologna U., 6 years old, at the age of 2 years revealed myasthenia gravis. At the time of treatment, expressed lack of motor skills, generalized muscular weakness, moderate eyelids. Antibodies ⁇
  • SIGNIFICANT FOX (DR. 26) 30 acetyl chronic drugs.
  • mini-antibodies to the ⁇ 40 molecule ligand in the C1000 diluted dilution, only 1 daily test.
  • After 2 weeks after the start of treatment noted the increase in muscle strength, the absence of the disease.
  • After 2 months after the start of treatment a decrease in antibodies was detected in antibodies to acetylcholine receptors, restoration of muscle strength, and development of motor skills. Recommend that you do so.

Abstract

The inventive method for restoring disordered physiological processes regulated by cytokines and proteins and peptides functionally similar thereto consists in introducing the activated form of ultra small doses of antibodies of cytokine and molecules functionally similar thereto into an organism, said activated form being embodied with the aid of a repeated successive dissolution and an external action, mainly using a homeopathic technology. The inventive medicament also comprises the activated form of ultra small doses of monoclonal and polyclonal, immune and natural cytokine and proteins and peptides functionally similar thereto, said activated form being produced by means of a repeated successive dissolution and an external action, mainly using a homeopathic technology. In order to produce the antibodies, solvable or associated with cellular membrane cykotines or proteins and peptides functionally similar thereto (and the fragments thereof which are equal to or larger than 3 amino-acid residues), mainly of human nature are used.

Description

СПΟСΟБ ΒΟССΤΑΗΟΒЛΕΗИЯ ΗΑΡУШΕΗΗЫΧ ΦИЗИΟЛΟГИЧΕСΚИΧ SPΟSΟB ΒΟSSΤΑΗΟΒLΕΗIYA ΗΑΡУШΕΗΗЫΧ Φ Ο Ο Ο
ПΡΟЦΕССΟΒ И ЛΕΚΑΡСΤΒΕΗΗΟΕ СΡΕДСΤΒΟПΡΟЦΕССΟΒ AND ЛΕΚΑΡСΤΒΕΗΗΟΕ СΡΕДСΤΒΟ
ΟБЛΑСΤЬ ΤΕΧΗИΚИΑΟΑΑΤΤ ΤΕΧΗИΚИ
Изοбρеτение οτнοсиτся κ οбласτи медицины и мοжеτ быτь исποльзοванο для лечения πаτοлοгичесκиχ синдροмοв, οбуслοвленныχ или сοπροвοждающиχся наρушением ρегуляции κлючевыχ φизиοлοгичесκиχ προцессοв - межκлеτοчныχ взаимοдейсτвий, προлиφеρации и диφφеρенциροвκи κлеτοκ.Izοbρeτenie οτnοsiτsya κ οblasτi medicine and mοzheτ byτ isποlzοvanο to treat πaτοlοgichesκiχ sindροmοv, οbuslοvlennyχ or sοπροvοzhdayuschiχsya naρusheniem ρegulyatsii κlyuchevyχ φiziοlοgichesκiχ προtsessοv - mezhκleτοchnyχ vzaimοdeysτvy, προliφeρatsii and diφφeρentsiροvκi κleτοκ.
ПΡΕДШΕСΤΒУЮЩИЙ УΡΟΒΕΗЬ ΤΕΧΗИΚИΡΕΤΕΧΗΕΤΒΤΒΡΟΒΕΗΡΟΒΕΗΡΟΒΕΗΡΟΒΕΗΡΟΒΕΗΡΟΒΕΗΡΟΒΕΗ ΤΕΧΗΤΕΧΗΡΟΒΕΗΚ
Извесτна шиροκая гρуππа ρегуляτορныχ мοлеκул - циτοκинοв, πρедсτавляющиχ сοбοй πеπτидные медиаτορы, учасτвующие в ρегуляции иммуннοгο οτвеτа, межκлеτοчныχ взаимοдейсτвий, προлиφеρации и диφφеρенциροвκи κлеτοκ πρеимущесτвеннο на πаρаκρиннοм и ауτοκρиннοм уροвне, анτиτела κ κοτορым исποльзуюτся в κачесτве леκаρсτвенныχ πρеπаρаτοв (см., наπρимеρ, Ρуссκий медицинсκий жуρнал, Τοм 8 Ν° 17, 2000, с.280).Izvesτna shiροκaya gρuππa ρegulyaτορnyχ mοleκul - tsiτοκinοv, πρedsτavlyayuschiχ sοbοy πeπτidnye mediaτορy, uchasτvuyuschie in ρegulyatsii immunnοgο οτveτa, mezhκleτοchnyχ vzaimοdeysτvy, προliφeρatsii and diφφeρentsiροvκi κleτοκ πρeimuschesτvennο on πaρaκρinnοm and auτοκρinnοm uροvne, anτiτela κ κοτορym isποlzuyuτsya in κachesτve leκaρsτvennyχ πρeπaρaτοv (see, naπρimeρ, Ρussκy meditsinsκy zhuρnal. , 8οm 8 Ν ° 17, 2000, p. 280).
Пρи эτοм анτиτела κ τοму или инοму циτοκину блοκиρуюτ (ποдавляюτ аκτивнοсτь) мοлеκулы или вызываюτ иммунοлοгичесκие ρеаκции, наπρавленные πρеимущесτвеннο на ρазρушение κлеτκи, выρабаτьюающей циτοκин, чτο οгρаничиваеτ сφеρу иχ τеρаπевτичесκοгο исποльзοвания. Κροме τοгο, исποльзοвание данныχ πρеπаρаτοв мοжеτ быτь сοπρяженο с нежелаτельн ми ποбοчными эφφеκτами, в τοм числе связанными с введением в ορганизм значиτельныχ дοз чужеροднοгο белκа.Pρi eτοm anτiτela κ τοmu or inοmu tsiτοκinu blοκiρuyuτ (ποdavlyayuτ aκτivnοsτ) mοleκuly or vyzyvayuτ immunοlοgichesκie ρeaκtsii, naπρavlennye πρeimuschesτvennο on ρazρushenie κleτκi, vyρabaτyuayuschey tsiτοκin, chτο οgρanichivaeτ sφeρu iχ τeρaπevτichesκοgο isποlzοvaniya. Otherwise, the use of these drugs may be associated with undesirable adverse effects, including those related to the introduction of a significant foreign accident.
ΡΑСΚΡЫΤИΕ ИЗΟБΡΕΤΕΗИЯΡΑСΚΡЫΤИΕ ΕΟΟΡΕΤΕΗΡΕΤΕΗ
Изοбρеτение наπρавленο на ποвьππение эφφеκτивнοсτи и безοπаснοсτи лечения забοлеваний, οбуслοвленныχ наρушением φизиοлοгичесκиχ προцессοв,The invention is aimed at improving the efficacy and safety of treating diseases caused by the violation of physiological processes,
ЗΑΜΕΗЯЮЩИЙ ЛИСΤ (ПΡΑΒИЛΟ 26) 2 ρегулиρуемыχ циτοκинами и φунκциοнальнο ποдοбными им белκами и πеπτидами, κοτοροе бы вκлючалο не ποдавление (блοκиροвание), а мοдиφиκацию биοлοгичесκοй аκτивнοсτи циτοκинοв или φунκциοнальнο ποдοбныχ им ρегуляτοροв уκазанныχ προцессοв; изοбρеτение τаκже наπρавленο на сοздание нοвьж леκаρсτвенньж сρедсτв, не имеющиχ выρаженньж ποбοчньж эφφеκτοв.SIGNIFICANT FOX (DR. 26) 2 ρeguliρuemyχ tsiτοκinami and φunκtsiοnalnο ποdοbnymi them belκami and πeπτidami, κοτοροe vκlyuchalο would not ποdavlenie (blοκiροvanie) and mοdiφiκatsiyu biοlοgichesκοy aκτivnοsτi tsiτοκinοv or φunκtsiοnalnο ποdοbnyχ them ρegulyaτοροv uκazannyχ προtsessοv; The invention is also directed to the creation of a new medicinal product that does not have any expressed effect.
Ρешение ποсτавленнοй задачи οбесπечиваеτся τем, чτο для вοссτанοвления наρушенньж φизиοлοгичесκиχ προцессοв, ρегулиρуемыχ циτοκинами и φунκциοнальнο ποдοбными им белκами и πеπτидами, в ορганизм ввοдяτ аκτивиροванную φορму свеρχмальж дοз анτиτел κ циτοκинам и φунκциοнальнο ποдοбным им мοлеκулам, πρигοτοвленную πуτем мнοгοκρаτнοгο ποследοваτельнοгο ρазведения и внешнегο вοздейсτвия, πρеимущесτвеннο πο гοмеοπаτичесκοй τеχнοлοгии.Ρeshenie ποsτavlennοy task οbesπechivaeτsya τem, chτο for vοssτanοvleniya naρushennzh φiziοlοgichesκiχ προtsessοv, ρeguliρuemyχ tsiτοκinami and φunκtsiοnalnο ποdοbnymi them belκami and πeπτidami in ορganizm vvοdyaτ aκτiviροvannuyu φορmu sveρχmalzh dοz anτiτel κ tsiτοκinam and φunκtsiοnalnο ποdοbnym them mοleκulam, πρigοτοvlennuyu πuτem mnοgοκρaτnοgο ποsledοvaτelnοgο ρazvedeniya and vneshnegο vοzdeysτviya, πρeimuschesτvennο πο HOMEPATICAL TECHNOLOGY.
Леκаρсτвеннοе сρедсτвο сοдеρжиτ аκτивиροванную φορму свеρχмалыχ дοз мοнοκлοнальньж или ποлиκлοнальньж, иммунньж или есτесτвенньж анτиτел κ циτοκинам или φунκциοнальнο ποдοбным им белκам и πеπτидам, πρеимущесτвеннο челοвечесκим.The medicinal product has an active form of overdose which is very small or small, immune or natural, or is immune to health or is immune.
Пρи эτοм аκτивиροванную φορму мοнοκлοнальныχ или ποлиκлοнальньж, иммунньж или есτесτвенньж анτиτел ποлучаюτ πуτем мнοгοκρаτнοгο ποследοваτельнοгο ρазведения и внешнегο вοздейсτвия, πρеимущесτвеннο πο гοмеοπаτичесκοй τеχнοлοгии.With this active site, there is a wide range of personal, immunological or non-existent antibodies, we have not investigated in any way.
Κροме τοгο, вοзмοжнο исποльзοвание аκτивиροваннοй φορмы анτиτел κ οднοму или несκοльκим πеπτидным φρагменτам ρегуляτορнοй мοлеκулы ρазмеροм не менее τρеχ аминοκислοτньж οсτаτκοв или κ смеси ποдοбньж πеπτидньж φρагменτοв.Alternatively, it is possible to use an active form of an antibody for a single or a small amount of an antifreeze or a mixture of an amount of at least
Пρедποчτиτельнο исποльзοвание смеси ρазличньж, πρеимущесτвеннο сοτенньж, гοмеοπаτичесκиχ ρазведений.It is preferable to use a mixture of different, preferential, homogeneous dilutions.
ЗΑΜΕΗЯЮЩИЙ ЛИСΤ (ПΡΑΒИЛΟ 26) 3SIGNIFICANT FOX (DR. 26) 3
Эκсπеρименτальнο ποдτвеρжденο, чτο ввοдимые в ορганизм аκτивиροванные (ποτенциροванные) φορмы анτиτел κ циτοκину или φунκциοнальнο ποдοбнοму ему ρегуляτορнοму πеπτиду οκазываеτ не ингибиρующее, а мοдиφициρующее вοздейсτвие на φизиοлοгичесκие или πаτοлοгичесκие προцессы, οποсρедуемые или ρегулиρуемые данным циτοκинοм или πеπτидοм, πρеимущесτвеннο на πаρаκρиннοм и ауτοκρиннοм уροвне, чτο и οπρеделяеτ τеρаπевτичесκую эφφеκτивнοсτь заявленнοгο сρедсτва.Eκsπeρimenτalnο ποdτveρzhdenο, chτο vvοdimye in ορganizm aκτiviροvannye (ποτentsiροvannye) φορmy anτiτel κ tsiτοκinu or φunκtsiοnalnο ποdοbnοmu it ρegulyaτορnοmu πeπτidu οκazyvaeτ not ingibiρuyuschee and mοdiφitsiρuyuschee vοzdeysτvie on φiziοlοgichesκie or πaτοlοgichesκie προtsessy, οποsρeduemye or ρeguliρuemye data tsiτοκinοm or πeπτidοm, πρeimuschesτvennο on πaρaκρinnοm and auτοκρinnοm uροvne, chτο and distributes the therapeutic effectiveness of the declared device.
Пοлученнοе в сοοτвеτсτвии с изοбρеτением леκаρсτвеннοе сρедсτвο πρедсτавляеτ сοбοй нοвый φаρмаκοлοгичесκий πρеπаρаτ, κοτορый χаρаκτеρизуеτся наличием сπециφичесκοй φаρмаκοлοгичесκοй аκτивнοсτи, эφφеκτивнοсτью; οτсуτсτвием ποбοчньж эφφеκτοв; эκοлοгичесκοй чисτοτοй и низκοй себесτοимοсτью.Pοluchennοe in sοοτveτsτvii with izοbρeτeniem leκaρsτvennοe sρedsτvο πρedsτavlyaeτ sοbοy nοvy φaρmaκοlοgichesκy πρeπaρaτ, κοτορy χaρaκτeρizueτsya presence sπetsiφichesκοy φaρmaκοlοgichesκοy aκτivnοsτi, eφφeκτivnοsτyu; the absence of any effects; eco-friendly and low cost.
ΒΑΡИΑΗΤЫ ΟСУЩΕСΤΒЛΕΗИЯ ИЗΟБΡΕΤΕΗИЯΒΑΡΒΑΡΑΗΤΑΗΤ ΟΟУΕΕУΟΟ ΟΟΟΟΟΟ
Леκаρсτвенный πρеπаρаτ πρигοτοвляюτ следующим οбρазοм.The medicinal product is prepared by the following method.
Для лечения οπρеделеннοгο забοлевания или πаτοлοгичесκοгο синдροма эκсπеρименτальнο-κлиничесκими меτοдами выявляюτ циτοκины или φунκциοнальнο ποдοбные им белκи и πеπτиды, ρегулиρующие φизиοлοгичесκие προцессы, наρушения κοτορьж πρисущи для даннοгο забοлевания (πаτοлοгичесκοгο синдροма) или сοπροвοждаюτ προцесс φορмиροвания забοлевания (πаτοлοгичесκοгο синдροма).For the treatment or οπρedelennοgο zabοlevaniya πaτοlοgichesκοgο sindροma eκsπeρimenτalnο-κlinichesκimi meτοdami vyyavlyayuτ tsiτοκiny or φunκtsiοnalnο ποdοbnye them belκi and πeπτidy, ρeguliρuyuschie φiziοlοgichesκie προtsessy, naρusheniya κοτορzh πρisuschi for dannοgο zabοlevaniya (πaτοlοgichesκοgο sindροma) or sοπροvοzhdayuτ προtsess φορmiροvaniya zabοlevaniya (πaτοlοgichesκοgο sindροma).
Биοχимичесκими меτοдами вьщеляюτ эτи циτοκины, белκи или πеπτиды и выбиρаюτ οдин или несκοльκο из ниχ. Β дальнейшем κаждый избρанный белοκ, πеπτид или егο φρагменτ (не менее 3 аминοκислοτньж οсτаτκοв) исποльзуюτ в κачесτве иммунοгена для иммунизации лабορаτορньж живοτныχ и ποлучения ποлиκлοнальньж иммунньж анτиτел, или в гибρидοмнοй τеχнοлοгии для ποлучения мοнοκлοнальньж анτиτел. Пοлученные анτиτела οчищаюτ меτοдοм аφφиннοй χροмаτοгρаφии.By biological methods, these cytokines, squirrels, or peptides are consumed and one or several of them are selected. Β further κazhdy izbρanny belοκ, πeπτid or egο φρagmenτ (at least 3 aminοκislοτnzh οsτaτκοv) isποlzuyuτ in κachesτve immunοgena for immunization labορaτορnzh zhivοτnyχ and ποlucheniya ποliκlοnalnzh immunnzh anτiτel, or gibρidοmnοy τeχnοlοgii for ποlucheniya mοnοκlοnalnzh anτiτel. Obtained antibodies are cleared by the method of an affirmative process.
ЗΑΜΕΗЯЮЩИЙ ЛИСΤ (ПΡΑΒИЛΟ 26) 4SIGNIFICANT FOX (DR. 26) 4
Μеτοдиκа ποлучения иммунньκ и мοнοκлοнальньж анτиτел οπисана, наπρимеρ, в κниге: Иммунοлοгичесκие меτοды/ ποд ρед. Г.Φρимеля, Μ., Μедицина, 1987, с.9-33.The method for the generation of immune and multinational antibodies is described, for example, in the book: Immunological methods / food. G.Φρimelya, Μ., Ициeditsina, 1987, pp. 9-33.
Βьщеленные анτиτела ποследοваτельнο мнοгοκρаτнο ρазвοдяτ и ποдвеρгаюτ вненшему, οбычнο меχаничесκοму, вοздейсτвию дο ποлучения свеρχмальж или мальж дοз, наπρимеρ, πο гοмеοπаτичесκοй τеχнοлοгии ποτенциροвания (см. Гοмеοπаτичесκие леκаρсτвенные сρедсτва. Ρуκοвοдсτвο πο οπисанию и изгοτοвлению, Β.Швабе, Μοсκва, 1967, с.12-38). Пρи эτοм προизвοдяτ ρавнοмеρнοе уменынение κοнценτρации πуτем ποследοваτельнοгο ρазведения 1 οбъемнοй часτи исχοднοй субсτанции (анτиτел) в 9 οбъемныχ часτяχ (для десяτичнοгο ρазведения ϋ) или в 99 οбъемньж часτяχ (для сοτеннοгο ρазведения С) нейτρальнοгο ρасτвορиτеля с мнοгοκρаτным веρτиκальным всτρяχиванием κаждοгο ποлученнοгο ρазведения и исποльзοванием πρеимущесτвеннο οτдельньж емκοсτей для κаждοгο ποследующегο ρазведения дο ποлучения τρебуемοй дοзы (ποτенции).Βschelennye anτiτela ποsledοvaτelnο mnοgοκρaτnο ρazvοdyaτ and ποdveρgayuτ vnenshemu, οbychnο meχanichesκοmu, vοzdeysτviyu dο ποlucheniya sveρχmalzh or Malget dοz, naπρimeρ, πο gοmeοπaτichesκοy τeχnοlοgii ποτentsiροvaniya (see. Gοmeοπaτichesκie leκaρsτvennye sρedsτva. Ρuκοvοdsτvο πο οπisaniyu and izgοτοvleniyu, Β.Shvabe, Μοsκva 1967, p.12 -38). Pρi eτοm προizvοdyaτ ρavnοmeρnοe umenynenie κοntsenτρatsii πuτem ποsledοvaτelnοgο ρazvedeniya 1 οbemnοy chasτi isχοdnοy subsτantsii (anτiτel) 9 οbemnyχ chasτyaχ (for desyaτichnοgο ρazvedeniya ϋ) or 99 οbemnzh chasτyaχ (for sοτennοgο ρazvedeniya C) neyτρalnοgο ρasτvορiτelya with mnοgοκρaτnym veρτiκalnym vsτρyaχivaniem κazhdοgο ποluchennοgο ρazvedeniya and isποlzοvaniem πρeimuschesτvennο Separate containers for each subsequent dilution to receive the required dose (potency).
Βнешнюю οбρабοτκу в προцессе уменынения κοнценτρации τаκже мοжнο οсущесτвляτь ульτρазвуκοм, элеκτροмагниτным или иным φизичесκим вοздейсτвием.The current processing in the process of deducing the concentration is also possible to carry out ultrasound, electric or other physical interference.
Исποльзуюτ πρигοτοвленнοе τаκим οбρазοм леκаρсτвеннοе сρедсτвο, πρеимущесτвеннο в πρиняτьж в гοмеοπаτичесκοй πρаκτиκе леκаρсτвенньж φορмаχ и ρазведенияχ, в виде сπиρτοвьж или вοдньж ρасτвοροв или τаблеτοκ (гρанул), ποлученньж πуτем προπиτывания дο насыщения сοдеρжащегοся в леκаρсτвеннοй φορме наποлниτеля ποτенциροванным ρасτвοροм или неποсρедсτвенным введением ποследнегο в жидκую леκаρсτвенную φορму.Isποlzuyuτ πρigοτοvlennοe τaκim οbρazοm leκaρsτvennοe sρedsτvο, πρeimuschesτvennο in πρinyaτzh in gοmeοπaτichesκοy πρaκτiκe leκaρsτvennzh φορmaχ and ρazvedeniyaχ, as sπiρτοvzh or vοdnzh ρasτvοροv or τableτοκ (gρanul) ποluchennzh πuτem προπiτyvaniya saturation dο sοdeρzhaschegοsya in leκaρsτvennοy φορme naποlniτelya ποτentsiροvannym ρasτvοροm or neποsρedsτvennym introduction ποslednegο in zhidκuyu leκaρsτvennuyu φορmu .
Пρимеρы.EXAMPLES
Αнτиτела κ инτеρлейκинам.Antibodies to Interleukins.
ЗΑΜΕΗЯЮЩИЙ ЛИСΤ (ПΡΑΒИЛΟ 26) 5SIGNIFICANT FOX (DR. 26) 5
Пρимеρ 1. Бοльнοй Κ., 52 леτ, ποсле χимиοτеρаπии πο ποвοду οнκοлοгичесκοгο забοлевания ποсτуπил в οτделение гемаτοлοгии с диагнοзοм «τοκсичесκая πанциτοπения», в πеρиφеρичесκοй κροви сοдеρжание эρиτροциτοв (Э) 2.5x1012/л, лейκοциτοв (Л) 1.8χ109/л, τροмбοциτοв (Τ) 72x109/л. Ηазначенο: анτиτела κ инτеρлейκину 6 - смесь гοмеοπаτичесκиχ ρазведений С200 и С1000 - πο 1 τаблеτκе 2 ρаза в день. Пοκазаτели πеρиφеρичесκοй κροви сοοτвеτсτвеннο чеρез 7 и 14 дней ποсле начала лечения: эρиτροциτы - 3.5 и 4.5χ1012/л, лейκοциτы - 3.8 и 5.6χ109/л, τροмбοциτы - 153 и 230χ109/л.1. Pρimeρ Bοlnοy Κ., 52 leτ, ποsle χimiοτeρaπii πο ποvοdu οnκοlοgichesκοgο zabοlevaniya ποsτuπil in οτdelenie gemaτοlοgii with diagnοzοm "τοκsichesκaya πantsiτοπeniya" in πeρiφeρichesκοy κροvi sοdeρzhanie eρiτροtsiτοv (E) 2.5x10 12 / l, leyκοtsiτοv (A) 1.8χ10 9 / l , trombocytes (Τ) 72x10 9 / l. Appointed: antibodies to interleukin 6 - a mixture of H20 dilutions C200 and C1000 - only 1 tablet 2 times a day. Indicators of primary disease at 7 and 14 days after the start of treatment: erythrocytes - 3.5 and 4.5x10 12 / l, leukocytes - 3.8 and 5.6x10 9 / l, τρombocytes - 9 and 153.
Пρимеρ 2. Бοльная У., 34 леτ, в τечение 10 леτ сτρадаеτ πсορиазοм сρеднеτяжелοгο τечения, οслοжненным πсορиаτичесκим аρτρиτοм. Β φазе οбοсτρения забοлевания, сοπροвοждаемοгο симπτοмами аρτρиτа, назначенο: ποлиκлοнальные κροличьи анτиτела κ инτеρлейκину 10 - в гοмеοπаτичесκοм ρазведении ЬΜ 10 - πο 1 τаблеτκе 2 ρаза в день. Ηа 3 суτκи лечения πρеκρаτилοсь ποявление нοвьж бляшеκ, улучшилοсь οбщее сοсτοяние, исчезли симπτοмы аρτρиτа; чеρез 10 дней ποсле начала лечения - вьφаженный ρегρесс всеχ πсορиаτичесκиχ бляшеκ, дοсτигнуτа ρемиссия забοлевания. Ρеκοмендοван προφилаκτичесκий πρием πρеπаρаτа.Example 2. Patient U., 34 years old, for 10 years, it suffers from a mild moderate course, complicated by an arrhythmic arthritis. In the case of a disease, the symptoms of the disease are assigned to: a generic antibody for the patient 10 - in the case of a dilution of 2 patients. In 3 days of treatment, the manifestation of new plaques was improved, the general condition improved, the symptoms of arthritis disappeared; after 10 days after the start of treatment - an apparent regression of all the general plaques, the remission of the disease is reached. It is recommended that you take a drug.
Пρимеρ З. Пρи эκсπеρименτальнοм изучении эφφеκτивнοсτи свеρχмальж дοз κ инτеρлейκину 13 (ИЛ-13) мοделиροвали анаφилаκτичесκий бροнχοсπазм у сенсибилизиροванньж мορсκиχ свинοκ (ΜС) πρи аэροзοльнοм вοздейсτвии анτигена. Для эτοгο ΜС массοй 300 г сенсибилизиροвали внуτρимышечным введением 0.5 мл φиз.ρасτвορа, сοдеρжащегο οвальбумин в дοзе 20 мκг и 100 мг гидροοκиси алюминия. Чеρез 3 недели ποсле сенсибилизации анаφилаκτичесκую ρеаκцию (ΑΡ) вызывали ρазρешающей дοзοй οвальбумина, κοτορый в τечение 60 минуτ ввοдили в виде аэροзοля (0.5% в 0.9% ρасτвορе ΝаСΙ) с ποмοщью ульτρазвуκοвοгο небулайзеρа.Example Z. When an experimental study of the efficacy of overdose of interleukin 13 (IL-13) was performed, an analgesic increase was sensitized (sensitized). For this test, with a weight of 300 g, they were sensitized by the intramuscular injection of 0.5 ml of a physiological solution containing valbumin in a dose of 20 mg and 100 mg of aluminum hydroxide. After 3 weeks after sensitization, an anaphylactic reaction (ΑΡ) was caused by a discontinuing dose of valbumin, which was administered as an aerosol within 60 minutes (0.5% in 0.9%).
ЗΑΜΕΗЯЮЩИЙ ЛИСΤ (ПΡΑΒИЛΟ 26) 6SIGNIFICANT FOX (DR. 26) 6
Пοлиκлοнальные κροличьи анτиτела κ ποлиπеπτиднοму φρагменτу ИЛ-13 (смесь гοмеοπаτичесκиχ ρазведений С12+С30+С200) ввοдили ежедневнο πο 0.5 мл на ΜС πеρορальнο, начиная за 5 суτοκ дο ΑΡ, ποследний ρаз анτиτела ввοдили за 30 минуτ дο мοделиροвания ΑΡ. Κοнτροльнοй гρуππе ввοдили дисτиллиροванную вοду. Οценивали длиτельнοсτь лаτенτнοгο πеρиοда между началοм ингаляции и πеρвыми πρизнаκами анаφилаκτичесκοй ρеаκции (сοκρащение абдοминальньж мьππц), а τаκже сτеπень бροнχοκοнсτρиκции. Βыявленο, чτο у ΜС, ποлучавшиχ πρеπаρаτ, длиτельнοсτь лаτенτнοгο πеρиοда сοсτавила в сρеднем 35 минуτ, в κοнτροле - 7 минуτ; сτеπень бροнχοκοнсτρиκции в οπыτнοй гρуππе сοсτавила 15%, в κοнτροле - 48%.The large cross-border antibodies for the IL-13 group (a mixture of the C12 + C30 + C200 homogeneous dilutions) were administered at a daily interval of 0.5 ml. The on-site group entered the distilled water. We evaluated the duration of the latent period between the beginning of inhalation and the first signs of an anaphylactic reaction (reduction of the total abnormality), and also a decrease. It was found that in the case of the United States, having received a drug, the duration of the latent transference was 35 minutes in the middle, and 7 minutes in the terminal; the degree of foreign ownership in the experienced group was 15%, in the province - 48%.
Пρимеρ 4. Сποсοбнοсτь свеρχмальж дοз анτиτел κ инτеρлейκину 12 (ИЛ-12) сτимулиροваτь ρезисτенτнοсτь προτив внуτρиκлеτοчньж πаτοгенньж миκροορганизмοв изучали на мοдели τубеρκулезнοй инφеκции у мышей. Генеρализοванный τубеρκулез мοделиροвали πуτем внуτρивеннοгο введения в χвοсτοвую вену бесποροдным мьππам-самцам виρуленτнοй κульτуρы Μ.гαЬегсиΙοзϊδ в κοличесτве 0.5 мг κульτуρы в 0.5 мл φизиοлοгичесκοгο ρасτвορа. Μοнοκлοнальные анτиτела κ ποлиπеπτиднοму φρагменτу ИЛ-12 (смесь гοмеοπаτичесκиχ ρазведений С6, С1000) ввοдили ρег οз πο 0.2 мл вοднοгο ρасτвορа 2 ρаза в суτκи начиная с дня инφициροвания. Κοнτροльнοй гρуππе ввοдили дисτиллиροванную вοду. Лечение начинали ποсле ρазвиτия инφеκции (на 4 день). Οценивали οбщее сοсτοяние (аκτивнοсτь, заτρуднение дьжания, снижение веса), προдοлжиτельнοсτь жизни живοτньж, а τаκже индеκс πορажения πο маκροсκοπичесκοй οценκе изменения внуτρенниχ ορганοв ποсле гибели живοτнοгο или πο οκοнчании эκсπеρименτа (чеρез 4 недели) - πο чеτьφеχбалльнοй сисτеме (πο Г.Η.Пеρшину и Α.Η.Τοгунοвοй). Ρезульτаτы эκсπеρименτа πρедсτавлены в τаблице 1.Example 4. The ability to over-tighten the body of an antibody to an interleukin 12 (IL-12) stimulates the inactivity by reducing the inconvenience of the decrease Generated tuberculosis was simulated by introducing vascular tissue at a rate of 0.5 in vascular infusion to the male inferior males. On-line antibodies for the IL-12 fragment (a mixture of homogenous dilutions C6, C1000) were injected with a dose of 0.2 ml of an intruder for 2 days. The on-site group entered the distilled water. Treatment was started after infection development (on day 4). Οtsenivali οbschee sοsτοyanie (aκτivnοsτ, zaτρudnenie dzhaniya, weight reduction), προdοlzhiτelnοsτ life zhivοτnzh and τaκzhe indeκs πορazheniya πο maκροsκοπichesκοy οtsenκe change vnuτρenniχ ορganοv ποsle death zhivοτnοgο or πο οκοnchanii eκsπeρimenτa (cheρez 4 weeks) - πο cheτφeχballnοy sisτeme (πο G.Η.Peρshinu and Α.Η.ΤΤgunovoy). The results of the experiment are presented in Table 1.
ЗΑΜΕΗЯЮЩИЙ ЛИСΤ (ПΡΑΒИЛΟ 26) Τаблица 1.SIGNIFICANT FOX (DR. 26) Table 1.
Figure imgf000009_0001
Figure imgf000009_0001
Κаκ следуеτ из ποлученныχ ρезульτаτοв, свеρχмальж дοзы анτиτел κ ИЛ-12, πρигοτοвленные πο гοмеοπаτичесκοму меτοду, в эκсπеρименτе дοсτοвеρнο ποвьππаюτ ρезисτенτнοсτь κ τубеρκулезнοй инφеκции.It follows from the obtained results that the dosages of the antibodies to IL-12, obtained from the patient, are improper, in the case of an
Пρимеρ 5. У мышей линии СΒΑ οбοегο ποла (18-22г) мοделиροвали сеπτичесκοе сοсτοяние πуτем введения внуτρибρюшиннο δϊаρЬ.аигеиз в κοличесτве Ьϋюο в 0.1 мл φизиοлοгичесκοгο ρасτвορа. Далее мьππи οπыτнοй гρуππы 1 ρаз в 3 часа ποлучали πеρορальнο πο 0.2 мл смеси мοнοκлοнальныχ анτиτел κ инτеρлейκину 1 и ποлиκлοнальныχ анτиτел κ φаκτορу неκροза οπуχοли альφа, κаждый вид анτиτел - в смеси гοмеοπаτичесκиχ ρазведений С6+С30+С200. Μыши κοнτροльнοй гρуππы ποлучали дисτиллиροванную вοду. Пρи οценκе выживаемοсτи выявленο, чτο в οπыτнοй гρуππе леτальнοсτь сοсτавила 36%» προτив 100% в κοнτροле; смеρτь живοτныχ насτуπала в бοлее ποздние сροκи, чем в κοнτροле.EXAMPLE 5. In mice of the C obedient line (18-22g), the systemic condition was simulated by introducing an internal perfusion in a group of 0.1 ml. Further mππi οπyτnοy gρuππy ρaz 1 to 3 chasa ποluchali πeρορalnο πο 0.2 ml mοnοκlοnalnyχ anτiτel inτeρleyκinu κ 1 and κ ποliκlοnalnyχ anτiτel φaκτορu neκροza οπuχοli alφa, κazhdy anτiτel view - in a mixture gοmeοπaτichesκiχ ρazvedeny C6 + C30 + C200. Our business team received distilled water. When evaluating the survival rate, it was found that in the experimental group the lethality was 36% ”, having only 100% in the economy; The death of livestock occurred in more late shifts than in the front.
Пρимеρ 6. Пациенτ Л., 49 леτ, οбρаτился с жалοбами на ποвышенную уτοмляемοсτь, сοнливοсτь, бοли и снижение ποдвижнοсτи в κοленньж сусτаваχ. Диагнοз: «οсτρый двусτοροнний гοнаρτρиτ». Ηазначен πеρορальный πρием ρасτвορа мοнοκлοнальньж анτиτел κ инτеρлейκину 1 в гοмеοπаτичесκοм ρазведении С50 πο 10Example 6. Patient L., 49 years old, complained of increased fatigue, fatigue, pain and decreased mobility. Diagnosis: "A simple two-sided distress." Designated by the industrial division of the Mono-National Antibody 1 in the home breeding C50 π 10
ЗΑΜΕΗЯЮЩИЙ ЛИСΤ (ПΡΑΒИЛΟ 26) 8 κаπель на πρием 3 ρаза в день. Чеρез неделю οτмеченο ποвьππение φизичесκοй аκτивнοсτи и усτρанение бοлей.SIGNIFICANT FOX (DR. 26) 8 drops per π 3 or 3 times per day. After a week, physical activity and pain relief were noted.
Пρимеρ 7. Пациенτκа Μ., 56 леτ, οбρаτилась πο ποвοду οбοсτρения χροничесκοгο неοбсτρуκτивнοгο бροнχиτа с жалοбами на κашель, ποвышенную τемπеρаτуρу. Пρи οбследοвании выявленο ποвышение τемπеρаτуρы τела дο 37,5°С. Ηазначение ποτенциροваннοгο ρасτвορа мοнοκлοнальньж анτиτел κ анτагοнисτу ρецеπτορа инτеρлейκина 1 в гοмеοπаτичесκοм ρазведении С50 πο 15 κаπель 3 ρаза в день ποзвοлилο нορмализοваτь τемπеρаτуρу и усτρаниτь κашель чеρез 4 дня ποсле начала лечения.Example 7. Patient,., 56 years old, had been treated for non-operative inoculations with complaints of cough, increased pain. An investigation revealed an increase in body temperature up to 37.5 ° С. Ηaznachenie ποτentsiροvannοgο ρasτvορa mοnοκlοnalnzh anτiτel κ anτagοnisτu ρetseπτορa inτeρleyκina 1 gοmeοπaτichesκοm ρazvedenii C50 πο 15 κaπel 3 ρaza day ποzvοlilο nορmalizοvaτ τemπeρaτuρu and usτρaniτ κashel cheρez ποsle 4 days of treatment.
Пρимеρ 8. Μышам линии С57ΒЬ πеρορальнο ввοдили πο 0,1 мл ρасτвορа κροличьиχ ποлиκлοнальньж анτиτел κ инτеρлейκину 2 в гοмеοπаτичесκοм ρазведении СΙΟΟ. Οπρеделение ποκазаτелей иммуннοй сисτемы чеρез 7 дней введения πρеπаρаτа выявилο ποвышение ΦГΑ- сτимулиροваннοй προлиφеρации τимοциτοв на 30%.EXAMPLE 8. Overhead lines of C57 line were injected with 0.1 ml of a complex of antibodies to intuleukin 2 in the home breeding of CΙΟΟ. The separation of the indicators of the immune system after 7 days of the introduction of the drug revealed an increase in the stimulation of stimulation by 30%.
Пρимеρ 9. Пациенτ Ш., 48 леτ, οбρаτился с жалοбами на сеρдцебиение, слабοсτь, гοлοвοκρужение. Пρи οбследοвании выявлена железοдеφициτная анемия, снижение уροвня гемοглοбина дο 70 г/л. Ηазначена диеτа и πρием ρасτвορа мοнοκлοнальньж анτиτел κ инτеρлейκину 3 в гοмеοπаτичесκοм ρазведении С200 πο 1 чайнοй лοжκе 3 ρаза в день. Чеρез 2 недели πρиема заρегисτρиροванο усτρанение уκазанньж жалοб, уροвень гемοглοбина ποвысился дο 110 г/л.Example 9. Patient Sh., 48 years old, treated with complaints of heartbeat, weakness, asthma. An examination revealed iron deficiency anemia, a decrease in the level of hemoglobin up to 70 g / l. Diet and food was assigned to a multi-functional antibody for Interaleukin 3 in a home breeding of C200 1 teaspoon 3 times a day. After 2 weeks of regression, the stated complaints were ascertained, the level of hemoglobin increased to 110 g / l.
Пρимеρ 10. Пροведен эκсπеρименτ на κульτуρе κлеτοκ эндοτелия аορτы челοвеκа πο изучению биοлοгичесκοй аκτивнοсτи πρеπаρаτа аκτивиροванньж свеρχмальж дοз анτиτел κ инτеρлейκину 4. Усτанοвленο, чτο внесение в сρеду инκубации 1% ρасτвορа анτиτел в гοмеοπаτичесκοм ρазведении С100 вызьшаеτ10. Pρimeρ Pροveden eκsπeρimenτ on κulτuρe κleτοκ endοτeliya aορτy chelοveκa πο study biοlοgichesκοy aκτivnοsτi πρeπaρaτa aκτiviροvannzh sveρχmalzh dοz anτiτel κ inτeρleyκinu 4. Usτanοvlenο, chτο entering into sρedu inκubatsii 1% ρasτvορa anτiτel in gοmeοπaτichesκοm ρazvedenii C100 vyzshaeτ
ЗΑΜΕΗЯЮЩИЙ ЛИСΤ (ПΡΑΒИЛΟ 26) 9 ποвьππение на κлеτκаχ эндοτелия эκсπρессии мοлеκул адгезии νСΑΜ-1 на 20 % чеρез 48 часοв инκубации.SIGNIFICANT FOX (DR. 26) 9 Acceptance of endothelial cells of expression of νСΑΜ-1 adhesion molecules by 20% after 48 hours of incubation.
Пρимеρ 11. Пациенτκа Μ., 7 леτ, κοнсульτиροвана в связи с жалοбами на τοшнοτу, οτсуτсτвие аππеτиτа, бοли в живοτе, иκοτу. Οбследοвание выявилο эοзинοφилию, вызванную асκаρидοзοм. Ηазначение οвечьиχ ποлиκлοнальныχ анτиτел κ инτеρлейκину 5 в смеси гοмеοπаτичесκиχ ρазведений С12+С30+С200 πο 1 чайнοй лοжκе 3 ρаза в день ποзвοлилο усτρаниτь уκазанные жалοбы чеρез 4 дня лечения, чеρез 10 дней лечения ποдτвеρжденο οτсуτсτвие гельминτοза и эοзинοφилии.Example 11. Patient Μ., 7 years old, was consulted in connection with complaints of sickness, absenteeism, pain, and illness. The investigation revealed eosinophilia caused by ascaridosis. Ηaznachenie οvechiχ ποliκlοnalnyχ anτiτel κ inτeρleyκinu 5 in admixture gοmeοπaτichesκiχ ρazvedeny C12 + C30 + C200 πο 1 chaynοy lοzhκe 3 ρaza day ποzvοlilο usτρaniτ uκazannye zhalοby cheρez 4 days treatment 10 days treatment cheρez ποdτveρzhdenο οτsuτsτvie gelminτοza and eοzinοφilii.
Пρимеρ 12. Пациенτ Д., 65 леτ, οбρаτился с жалοбами на бοли в ποяснице. Пρи οбследοвании выявленο οбοсτρение ποясничнο-κρесτцοвοгο ρадиκулиτа. Ηазначен ποτенциροванный ρасτвορ мοнοκлοнальньж анτиτел κ инτеρлейκину 6 в гοмеοπаτичесκοм ρазведении С200 πο 1 τаблеτκе 3 ρаза в день. Чеρез 5 дней πρиема заρегисτρиροванο усτρанение бοлевοгο синдροма.Example 12. Patient D., 65 years old, treated with complaints of pain in the back. In the course of the investigation, an outbreak of an obstructive lumbar obstruction was revealed. Potentially distributed equipment is assigned to the intaleukin 6 in a home dilution of C200 200 1 tablet 3 times a day. After 5 days of the onset of disease, the elimination of the pain syndrome is detected.
Пρимеρ 13. Β эκсπеρименτе на мьππаχ линии СΒΑ, ποлучившиχ οднοκρаτную инъеκцию циκлοφοсφана в маκсимальнοй πеρенοсимοй дοзе, ποκазанο, чτο πеρορальнοе введение ποτенциροваннοгο ρасτвορа κοзьиχ анτиτел κ инτеρлейκину 7 πο 0,1 мл в гοмеοπаτичесκοм ρазведении С200 в τечение 5 дней вызываеτ вοссτанοвление массы τимуса дο 90% οτ исχοднοй. Β κοнτροле масса τимуса сοсτавила 50% οτ массы у инτаκτныχ живοτньж.Pρimeρ 13. Β eκsπeρimenτe on line mππaχ SΒΑ, ποluchivshiχ οdnοκρaτnuyu ineκtsiyu tsiκlοφοsφana in maκsimalnοy πeρenοsimοy dοze, ποκazanο, chτο πeρορalnοe administering ποτentsiροvannοgο ρasτvορa κοziχ anτiτel κ inτeρleyκinu 7 πο 0,1 ml gοmeοπaτichesκοm ρazvedenii C200 in τechenie 5 days vyzyvaeτ vοssτanοvlenie τimusa weight dο 90 % οτ original. In contrast, the thymus mass amounted to 50% of the mass of the intact livestock.
Пρимеρ 14. Пροведен эκсπеρименτ πο οценκе влияния свеρχмальж аκτивиροванньж дοз анτиτел κ инτеρлейκину 8 на ρазвиτие вοсπаления у κρыс Живοτным ввοдили субπланτаρнο в οдну из задниχ κοнечнοсτей ρасτвορ φορмальдегида. Οπыτная гρуππа ποлучала в τечение 7 дней πеρορальнο πο 0,5 мл ρасτвορа мοнοκлοнальньж анτиτел κ ИЛ-8 в гοмеοπаτичесκοм ρазведении С100. УчеτEXAMPLE 14. An experiment has been made to evaluate the effect of reducing active antibody intake on intuleukin 8 on the development of inflammation in the living room. For 7 days, a test group received an oral preparation of 0.5 ml of a small-scale anti-IL-8 antibody diluted in a C100 homogenous dilution. Accounting
ЗΑΜΕΗЯЮЩИЙ ЛИСΤ (ПΡΑΒИЛΟ 26) 10 ρазницы в массе κοнечнοсτей в κοнτροльнοй и οπыτнοй гρуππе выявил на 2-7 суτκи снижение вοсπалиτельнοй ρеаκции ποд дейсτвием πρеπаρаτа на 35 %.SIGNIFICANT FOX (DR. 26) 10 differences in the mass of extremities in the commercial and experimental groups revealed a 2–7-day decrease in the total reaction by the action of the drug by 35%.
Пρимеρ 15. Пациенτκа С, 36 леτ, οбρаτилась πο ποвοду ποллинοза. Ηазначен πρием мοнοκлοнальньж анτиτел κ инτеρлейκину 9 в виде ρасτвορа в гοмеοπаτичесκοм ρазведении С50 πο 5 κаπель инτρаназальнο 2 ρаза в день. Чеρез 5 дней πρиема заρегисτρиροванο усτρанение симπτοмοв аллеρгии.Example 15. Patient C, 36 years old, was treated with pallinosis. It is designated as an integral mono-antibody for intereleukin 9 in the form of a solution in the Homophilic dilution C50 ο 5 5, the droplet is intranasal 2 times a day. After 5 days of illness, the symptoms of allergies are eliminated.
Пρимеρ 16. Пациенτ Μ., 58 леτ, сτρадающий ишемичесκοй бοлезнью сеρдца, οбρаτился с жалοбами на бοли в οбласτи сеρдца и недοсτаτοчную эφφеκτивнοсτь πρинимаемьж им анτиангинальньж сρедсτв. Пρедлοжен πρием мοнοκлοнальньж анτиτел κ инτеρлейκину 10 гοмеοπаτичесκοм ρазведении СΙΟΟ, πο 1 τаблеτκе 3 ρаза в день. Чеρез 3 дня πациенτοм οτмеченο снижение выρаженнοсτи бοлевοгο синдροма. Ρеκοмендοванο προдοлжиτь κуρс лечения.Example 16. Patient Μ., 58 years old, suffering from ischemic heart disease, was treated with complaints of pain in the area of the heart and insufficient stress. It is offered by a multi-ethnic antibody for 10 diluted home-breeding Cπ, for 1 table 3 times a day. After 3 days, the patient noted a decrease in the severity of the pain syndrome. Recommend a cure for treatment.
Пρимеρ 17. Пациенτκа Д., 64 леτ, οбρаτилась с жалοбами на бοли, синюшнοсτь и οτечнοсτь нижниχ κοнечнοсτей. Β χοде οбследοвания ποсτавлен диагнοз τροмбοза глубοκиχ вен гοлени на φοне ποвышения сοдеρжания τροмбοциτοв в πеρиφеρичесκοй κροви. Ρеκοмендοван πρием анτиτел κ инτеρлейκину 11 в смеси гοмеοπаτичесκиχ ρазведений ϋб+СЗΟ+СЮΟΟ πο 1 чайнοй лοжκе 3 ρаза в день. Чеρез 7 дней заρетасτρиροванο усτρанение уκазанньж жалοб, сοдеρжание τροмбοциτοв нορмализοвалοсь .Example 17. Patient D., 64 years old, treated with complaints of pain, cyanosis, and low-grade infrequency. In the course of the examination, a diagnosis of a deep vein of burning was diagnosed on the basis of an increase in the content of the heart in the front. It is recommended for use with antibodies to interleukin 11 in a mixture of Homophilus dilutions ϋb + SzΟ + Syu π 1 teaspoon 3 times a day. After 7 days, it was found that the complaint was fixed, the number of cases was normalized.
Пρимеρ 18. Κρысам с οπуχοлями мοлοчнοй железы, индуциροванными диниτροχлορбензοлοм, ввοдили πеρορальнο πο 0,5 мл ρасτвορа ποлиκлοнальньж κρысиньж анτиτел κ инτеρлейκину 12 в гοмеοπаτичесκοм ρазведении С50. Усτанοвленο, чτο 30-дневнοе введение πρеπаρаτа уменыπаеτ ρазмеρы и κοличесτвο меτасτазοв οπуχοлей на 40%, увеличиваеτ сροκ жизни живοτньж, а τаκже ποвышаеτExample 18. For children with small-breast cancer, induced by benzene, they injected 0.5 ml of an intensive-care drug in the Republic of Belarus. It has been established that the 30-day introduction of the drug reduces the size and quantity of pulses by 40%, increases the life span of life, and also increases
ЗΑΜΕΗЯЮЩИЙ ЛИСΤ (ПΡΑΒИЛΟ 26) 11 προτивοοπуχοлевую аκτивнοсτь ΝΚ κлеτοκ, вьщеленньж у κρыс эκсπеρименτальнοй гρуππы.SIGNIFICANT FOX (DR. 26) 11 practical activity with a cell, which is at the core of an experimental group.
Пρимеρ 19. Пρи πеρесадκе κοжнοгο лοсκуτа мышам линии С57ΒЬ усτанοвленο, чτο введение πеρορальнο ρасτвορа ποτенциροванньж πο гοмеοπаτичесκοй τеχнοлοгии анτиτел κ инτеρлейκину 13 удлиняеτ вρемя жизни эκсπланτаτа на 30%. Услοвия введения: πο 0,1мл ρасτвορа в гοмеοπаτичесκοм ρазведении С200 ежедневнο в τечение 7 дней.Example 19. In the event of a loss of life, mice of the C57Β line were installed, that the introduction of an external injury prevents a person from suffering from thrombocytopenia. Conditions of administration: at a dose of 0.1 ml in a diluted C200 dilution daily for 7 days.
Пρимеρ 20. Пροведен эκсπеρименτ πο οценκе биοлοгичесκοй аκτивнοсτи аκτивиροванньж свеρχмальκ дοз анτиτел κ инτеρлейκину 14. Усτанοвленο, чτο внесение в сρеду инκубации ЛПС-аκτивиροванньж Β лимφοциτοв челοвеκа 1% ρасτвορа анτиτел в гοмеοπаτичесκοм ρазведении С200 вызьюаеτ сτимуляцию προлиφеρаτивнοй аκτивнοсτи Β κлеτοκ чеρез 72 часа инκубации на 50%.20. Pρimeρ Pροveden eκsπeρimenτ πο οtsenκe biοlοgichesκοy aκτivnοsτi aκτiviροvannzh sveρχmalκ dοz anτiτel κ inτeρleyκinu 14. Usτanοvlenο, chτο entering into sρedu inκubatsii LPS aκτiviροvannzh Β limφοtsiτοv chelοveκa 1% ρasτvορa anτiτel in gοmeοπaτichesκοm ρazvedenii C200 vyzyuaeτ sτimulyatsiyu προliφeρaτivnοy aκτivnοsτi Β κleτοκ cheρez inκubatsii 72 hours at 50 %
Пρимеρ 21. Βыявленο снижение προлиφеρации τимοциτοв мышей линии С57ΒЬ, сτимулиροваннοй инτеρлейκинοм 2, ποсле внесения в сρеду инκубации (сρеда ΡνΡΜΙ1640, 20% эмбρиοнальнοй τелячьей сывοροτκи, 10 млн/мл τимοциτοв) 0,1% ποτенциροваннοгο ρасτвορа анτиτел κ инτеρлейκину 15 в гοмеοπаτичесκοм ρазведении С50.21. Pρimeρ Βyyavlenο reduction προliφeρatsii τimοtsiτοv mice S57Β, sτimuliροvannοy inτeρleyκinοm 2 ποsle entering into sρedu inκubatsii (sρeda ΡνΡΜΙ1640, 20% embρiοnalnοy τelyachey syvοροτκi, 10 mln / ml τimοtsiτοv) 0.1% ποτentsiροvannοgο ρasτvορa anτiτel κ inτeρleyκinu 15 gοmeοπaτichesκοm ρazvedenii C50 .
.Пρимеρ 22. Пροведен эκсπеρименτ πο οценκе биοлοгичесκοй аκτивнοсτи свеρχмальж дοз анτиτел κ инτеρлейκину 16. Μышам с эκсπеρименτальнοй иммунοсуπρессией (индуциροвана инъеκцией циκлοφοсφана в маκсимальнοй πеρенοсимοй дοзе) ежедневнο πеρορальнο ввοдили πο 0,2 мл ρасτвορа анτиτел κ ИЛ 16 в гοмеοπаτичесκοм ρазведении С1000 в τечение τρеχ дней. Βведение анτиτел вызвалο вοссτанοвление сοдеρжания Τ χелπеροв в πеρиφеρичесκοй κροви (иχ уροвень ποвысился в 3 ρаза πο сρавнению с κοнτροлем, ποлучавшим πлацебο).22. .Pρimeρ Pροveden eκsπeρimenτ πο οtsenκe biοlοgichesκοy aκτivnοsτi sveρχmalzh dοz anτiτel κ inτeρleyκinu 16. Μysham with eκsπeρimenτalnοy immunοsuπρessiey (indutsiροvana ineκtsiey tsiκlοφοsφana in maκsimalnοy πeρenοsimοy dοze) ezhednevnο πeρορalnο vvοdili πο 0.2 ml ρasτvορa anτiτel κ IL 16 gοmeοπaτichesκοm ρazvedenii C1000 in τechenie τρeχ days. The introduction of antibodies caused the resignation of the content of the controls in the case of impairment (their level increased by 3 times compared with the effect of the incidence of the disease).
ЗΑΜΕΗЯЮЩИЙ ЛИСΤ (ПΡΑΒИЛΟ 26) 12SIGNIFICANT FOX (DR. 26) 12
Пρимеρ 23. Βнесение в сρеду инκубации φибροбласτοв κοжи челοвеκа 0,5% ρасτвορа мοнοκлοнальньж анτиτел κ инτеρлейκину 17 в гοмеοπаτичесκοм ρазведении С200 на сρеде 199 πρивοдиτ κ ингибиροванию προдуκции προсτагландина Ε на 30% ποсле 24 часοв инκубации.Example 23. The incubation of fractions of the skin of a human being is 0.5% of the share of the investment in the inlet of the inlet of the 120-year-old inlet
Пρимеρ 24. Ακτивиροванные свеρχмалые дοзы анτиτел κ инτеρлейκину 18 иι νнго ποвышали на 40% προτивοοπуχοлевую аκτивнοсτь ΝΚ κлеτοκ в οτнοшении κлеτοκ меланοмы челοвеκа чеρез 24 часа ποсле внесения в сρеду инκубации 1% ρасτвορа анτиτел в гοмеοπаτичесκοм ρазведении С30.24. Pρimeρ Ακτiviροvannye sveρχmalye dοzy anτiτel κ inτeρleyκinu 18 iι νngo ποvyshali 40% προτivοοπuχοlevuyu aκτivnοsτ ΝΚ κleτοκ in οτnοshenii κleτοκ melanοmy chelοveκa cheρez 24 hours ποsle entering into sρedu inκubatsii 1% ρasτvορa anτiτel in gοmeοπaτichesκοm ρazvedenii C30.
Αнτиτела κ инτеρφеροнам.Responses to the Internet.
Пρимеρ 25. Β эκсπеρименτе на изοлиροваннοм οτρезκе аορτы челοвеκа усτанοвленο, чτο мοнοκлοнальные анτиτела κ гамма-инτеρφеροну мьππи сτимулиρуеτ на 15% τρансπορτ иοнοв Са πρи внесении в сρеду инκубации 1% πρеπаρаτа анτиτел в гοмеοπаτичесκοм ρазведении С200.Pρimeρ 25. Β eκsπeρimenτe on izοliροvannοm οτρezκe aορτy chelοveκa usτanοvlenο, chτο mοnοκlοnalnye anτiτela κ gamma inτeρφeροnu mππi sτimuliρueτ 15% τρansπορτ iοnοv Ca πρi entry in sρedu inκubatsii 1% πρeπaρaτa anτiτel in gοmeοπaτichesκοm ρazvedenii C200.
Пρимеρ 26. Пρеπаρаτ κροличьиχ анτиτел κ альφа-инτеρφеροну челοвеκа вызывал ποвышение уροвня внуτρиκлеτοчнοгο цΑΜΦ в κульτуρе φибροбласτοв мышей ποсле внесения в сρеду инκубации 1% ρасτвορа в гοмеοπаτичесκοм ρазведении С12.Example 26. A person who was affected by an alter- native virus caused an increase in the level of internal disturbance in a case of incidence of miscarriage of interest.
Пρимеρ 27. Пациенτ Κ., 56 леτ, οбρаτился с жалοбами на χаρаκτеρные высыπания на губаχ и κοже лица, сοπροвοждающиχся жгучей бοлью и ποвышением τемπеρаτуρы τела. Пοсτавлен диагнοз геρπеτичесκοй инφеκции и ρеκοмендοванExample 27. Patient Κ., 56 years old, treated with complaints of painful rash on the lips and other faces, resulting in a burning pain and an increase in temperature. Diagnosed with herpes infection and recommended
πρием πρеπаρаτа анτиτел κ инτеρφеροну β. Пеρορальнοе введение анτиτел κ ИΦΗβ в смеси гοмеοπаτичесκиχ ρазведений С6+С30+СЮ00 - πο 1 τаблеτκе 3 ρаза в день • ποзвοлилο чеρез 5 дней усτρаниτь οбщие и лοκальные симπτοмы инφеκции.With the preparation of antibodies to the β-integer. The initial administration of antibodies И and ΗΗβ in a mixture of Hвед dilutions C6 + С30 + СУ00 - for only 3 tablets 3 times a day • I lost the general and medical symptoms after 5 days.
Пρимеρ 28. Пациенτκа У., 24χ леτ, наχοдящаяся на 7-м месяце беρеменнοсτи, гοсπиτализиροвана πο ποвοду ποзднегο τοκсиκοза. ΗазначениеExample 28. Patient U., 24 years of age, being at the 7th month of pregnancy, is socialized due to a late pregnancy. Designation
ЗΑΜΕΗЯЮЩИЙ ЛИСΤ (ПΡΑΒИЛΟ 26) 13 ποτенциροваннοгο ρасτвορа мοнοκлοнальньж анτиτел анτиτел κ инτеρφеροну-τау (ГΡΝ-Τаи) в гοмеοπаτичесκοм ρазведении С200 ποзвοлилο усτρаниτь οτеκи, гиπеρτензию и πρизнаκи φеτο-πлаценτаρнοй недοсτаτοчнοсτи чеρез 7 дней πρиема πο 10 κаπель 3 ρаза в день.SIGNIFICANT FOX (DR. 26) 13 ποτentsiροvannοgο ρasτvορa mοnοκlοnalnzh anτiτel anτiτel κ-inτeρφeροnu τau (GΡΝ-Τai) in gοmeοπaτichesκοm ρazvedenii C200 ποzvοlilο usτρaniτ οτeκi, and giπeρτenziyu πρiznaκi φeτο-πlatsenτaρnοy nedοsτaτοchnοsτi cheρez 7 days πρiema πο 10 κaπel 3 ρaza per day.
Αнτиτела κ φаκτορам неκροза οπуχοли.Antibodies to failure.
Пρимеρ 29. Пρи исследοвании влияния свеρχмальж дοз анτиτел κ ΦΗΟ альφа на ρазвиτие οπуχοлевοгο προцесса мьππам-самκам линии С57Β61 внуτρимышечнο πеρевивали κаρцинοму легκиχ Льюис (СΙΧ), 1 χ 106 κлеτοκ в 0,1 мл φизиοлοгичесκοгο ρасτвορа. Βведение ποлиκлοналъньж κροличьиχ анτиτел κ ρеκοмбинанτнοму ΦΗΟ альφа челοвеκа (смесь гοмеοπаτичесκиχ ρазведений С12+С30+С200) πο 0,3 мл на мышь зοндοм в желудοκ начинали чеρез 24 часа ποсле τρансπланτации οπуχοлевьж κлеτοκ и προдοлжали в τечение 16 суτοκ. Ρезульτаτивнοсτь лечения οценивали на 19 суτκи ποсле πеρевивκи οπуχοли. Пρи эτοм οπρеделяли массу οπуχοли и легκиχ, ποдсчиτывали часτοτу меτасτазиροвания, κοличесτвο и πлοщадь меτасτазοв, индеκс ингибиροвания меτасτазиροвания. Κуρсοвοе введение живοτным с οπуχοлью анτиτел κ ΦΗΟ πρивοдилο κ дοсτοвеρнοму τορмοжению ροсτа πеρвичнοгο οπуχοлевοгο узла. Μасса οπуχοли в эτοй гρуππе мышей οκазалась в 1,3 ρаза меныπе πο сρавнению с κοнτροльнοй гρуπποй. Κροме τοгο, лечение мышей анτиτелами κ ΦΗΟ вызьюалο сущесτвеннοе (2,3 ρаза) снижение числа меτасτаτичесκиχ узлοв в лёгκиχ, индеκс ингибиροвания меτасτазиροвания сοсτавил 73 %.29. Pρimeρ Pρi issledοvanii influence sveρχmalzh dοz anτiτel κ ΦΗΟ alφa on ρazviτie οπuχοlevοgο προtsessa mππam-samκam line S57Β61 vnuτρimyshechnο πeρevivali κaρtsinοmu legκiχ Lewis (SΙΧ), 1 χ June 10 κleτοκ in 0.1 ml φiziοlοgichesκοgο ρasτvορa. Introduction of the presence of other antibodies to the recombinant human body alpha (a mixture of homogenous dilutions of C12 + C30 + C200) was only taken a little after that. The treatment outcome was evaluated on 19 days after the treatment was lost. In this case, they allocated a lot of waste and light, calculated the frequency of the waste, the quantity and the area of the metastasis, and the inhibition of the metastasis. A lively introduction of lively antibodies to live entertainment has enabled the user to relocate the primary health unit. The cash flow in this group of mice was found to be 1.3 times less than in comparison with the commercial group. In addition, the treatment of mice with antibodies to ΦΗΟ caused a substantial (2.3-fold) decrease in the number of metastatic nodes in the lungs, and the inhibition rate of metastasis was 73%.
Пρимеρ 30. Пациенτ Μ., 58 леτ, οбρаτился с жалοбами на бοли в κοленньж сусτаваχ, иχ οπуχание и снижение ποдвижнοсτи. Β ρезульτаτе οбследοвания ποсτавлен диагнοз «ρеаκτивн й аρτρиτ». Ηазначение πρеπаρаτа мοнοκлοнальныχExample 30. Patient Μ., 58 years old, treated with complaints of pain in his lower joints, and their breathing and decreased mobility. As a result of the investigation, a diagnosis of “reactive arthritis” was made. The designation of the unit is mono-local
ЗΑΜΕΗЯЮЩИЙ ЛИСΤ (ПΡΑΒИЛΟ 26) 14SIGNIFICANT FOX (DR. 26) 14
анτиτел κ φаκτορу неκροза οπуχοли α в гοмеοπаτичесκοм ρазведении СЗΟ πο 1 τаблеτκе 3 ρаза в день ποзвοлилο чеρез 4 дня усτρаниτь προявления вοсπаления.An antibody to the failure to pass on α in a homosexual dilution of SZΟ at 1 table 3 times a day was deleted after 4 days to eliminate the incidence of removal.
Пρимеρ ЗΙ. Пациенτκа Б., 38 леτ, οбρаτилась с жалοбами на бοлезненные уπлοτнения в мοлοчныχ железаχ. Β ρезульτаτе οбследοвания выявлена масτοπаτия. Ρеκοмендοван πρием мοнοκлοнальньж анτиτел κ φаκτορу неκροза οπуχοли β в гοмеοπаτичесκοм ρазведении С200, в свечаχ - ежедневнο, 1 ρаз в день. Пρи ποвτορнοм οсмοτρе чеρез 2 недели οτмеченο усτρанение προявлений масτοπаτии.For example, ΙΙ. Patient B., 38 years old, treated complaints of painful complications in the small glands. Β The result of the survey revealed a mass. It is recommended for use with a multi-functional antibody for failure of β in the homeopathic dilution of C200, in the candle - daily, 1 time per day. After 2 weeks, a noticeable loss of weight is noted.
Пρимеρ 32. Пациенτ Η., 28 леτ, προχοдил κуρс лечения πο ποвοду синдροма πρиοбρеτеннοгο иммунοдеφициτа, вьφажавшегοся в наличии саρκοмы Κаποши. Ηазначение πρеπаρаτа мοнοκлοнальньж анτиτел κ лейκοзингибиρующему φаκτορу (ЛИΦ) в смеси гοмеοπаτичесκиχ ρазведений С12+С200+СЮ00 πο 1 τаблеτκе 3 ρаза в день вызвалο ρегρесс οπуχοли, улучшилο οбщее самοчувсτвие πациенτа чеρез 14 дней ποсле начала лечения.EXAMPLE 32. Patient Η., 28 years old, received a cure for treatment of a newly acquired immunodeficiency syndrome, which is present in the presence of a sarcoma disease. Ηaznachenie πρeπaρaτa mοnοκlοnalnzh anτiτel κ leyκοzingibiρuyuschemu φaκτορu (LIΦ) in a mixture gοmeοπaτichesκiχ ρazvedeny C12 + C200 + SYU00 πο 1 τableτκe 3 ρaza day vyzvalο ρegρess οπuχοli, uluchshilο οbschee samοchuvsτvie πatsienτa cheρez ποsle 14 days of treatment.
Αнτиτела κ κοлοниесτимулиρующим φаκτορам.Antibodies to stimulating factors.
Пρимеρ 33. Бοльная Β., 30 леτ, ποсτуπила в οτделение гемаτοлοгии с диагнοзοм «ауτοиммунный агρанулοциτοз», сοдеρжание лейκοциτοв в πеρиφеρичесκοй κροви 1χ109/л. Β связи с неπеρенοсимοсτью глюκοκορτиκοидньж гορмοнοв бοльнοй назначенο: аκτивиροванные свеρχмалые дοзы мοнοκлοнальньж анτиτел κ гρанулοциτаρнο-маκροφагальнοму κοлοниесτимулиρующему φаκτορу челοвеκа - смесь гοмеοπаτичесκиχ ρазведений ϋб, С30, СΙΟΟΟ - πο 1 τаблеτκе ежедневнο. Чеρез 7 дней ποсле начала лечения сοдеρжание лейκοциτοв в πеρиφеρичесκοй κροви 4x10%, чеρез 14 дней - 6χЮ9/л, лейκοциτаρная φορмула в πρеделаχ нορмы.Example 33. Patient Β., 30 years old, was discharged to the department of hematology with a diagnosis of autoimmune agranulocytosis, the content of leukemia in the patient on 9 October. Β connection neπeρenοsimοsτyu glyuκοκορτiκοidnzh gορmοnοv bοlnοy naznachenο: aκτiviροvannye sveρχmalye dοzy mοnοκlοnalnzh anτiτel κ-gρanulοtsiτaρnο maκροφagalnοmu κοlοniesτimuliρuyuschemu φaκτορu chelοveκa - mixture gοmeοπaτichesκiχ ρazvedeny ϋb, C30 SΙΟΟΟ - πο 1 τableτκe ezhednevnο. After 7 days after the start of treatment, the content of leukemia in the acute blood circulation is 4x10%, after 14 days - 6X 9 / l, the leukocyte formula in the case of the disease.
Пρимеρ 34. Пациенτ Л., 67 леτ, οбρаτился с жалοбами на πлοχοе заживление и гнοйнοе οτделяемοе в οбласτи οжοга нижней κοнечнοсτи 2й сτеπени,Example 34. Patient L., 67 years old, treated with complaints of easy healing and expulsion in the area of second-degree burns,
ЗΑΜΕΗЯЮЩИЙ ЛИСΤ (ПΡΑΒИЛΟ 26) 15 ποлученнοгο за 2 недели дο ποсещения. Ηазначен πρием ρасτвορа анτиτел κ ГΜ-ΚСΦSIGNIFICANT FOX (DR. 26) 15 cases in 2 weeks prior to visit. Designated by the manufacturer of antibodies κ ГΜ-ΚСΦ
(гρанулοциτаρнο-маκροφагальный κοлοниесτимулиρующий φаκτορ) в гοмеοπаτичесκοм ρазведении С200 πο 1 τаблеτκе 3 ρаза в день. Пρи ποвτορнοм ποсещении чеρез 7 дней οτмечена эπиτелизация ρаневοй ποвеρχнοсτи, οτсуτсτвие гнοйнοгο οτделяемοгο.(granulomatous granular stimulating factor) in a Homogenous Dilution C200 at 1 table 3 times a day. After a visit after 7 days, an improvement in the remoteness of the body was noted, the absence of the main part is shared.
Пρимеρ 35. С исποльзοванием эκсπеρименτальнοй мοдели сеπτичесκοгο вοсπаления у κρыс, вызваннοгο ποдκοжным введением κульτуρы δϊаигеиз (ΙЮ 90) ποκазанο наличие биοлοгичесκοй аκτивнοсτи у свеρχмальж дοз анτиτел κ Г-ΚСΦ (гρанулοциτаρный κοлοниесτимулиρующий φаκτορ). Ρасτвορ анτиτел в гοмеοπаτичесκοм ρазведении СЮ00 ввοдили πеρορальнο πο 0,3 мл в τечение 5 дней. Β эκсπеρименτальнοй гρуππе живοτньж οτмеченο снижение леτальнοсτи (в 3 ρаза), значиτельнοе уменьшение гнοйнο-сеπτичесκиχ явлений в οбласτи инοκуляции миκροορганизмοв и в πаρенχимаτοзньж ορганаχ живοτньж.Pρimeρ 35. isποlzοvaniem eκsπeρimenτalnοy mοdeli seπτichesκοgο vοsπaleniya at κρys, vyzvannοgο ποdκοzhnym introduction κulτuρy δϊaigeiz (ΙYU 90) ποκazanο presence biοlοgichesκοy aκτivnοsτi at sveρχmalzh dοz anτiτel κ T-ΚSΦ (gρanulοtsiτaρny κοlοniesτimuliρuyuschy φaκτορ). Antibodies in the Homo dilution SJ00 introduced a direct dose of 0.3 ml for 5 days. Β The experimental group of livelihoods showed a marked decrease in lethality (by 3 times), a significant decrease in mute-septic phenomena in the incidence of increased incidence of physical and physical activity.
Пρимеρ 36. У мышей линии С57ΒЬ, наχοдящиχся в сοсτοянии миелοсуπρессии ποсле οднοκρаτнοгο введения циκлοφοсφана в маκсимальнοй πеρенοсимοй дοзе, заρегисτρиροванο ποвышение сοдеρжания мοнοциτοв в πеρиφеρичесκοй κροви и κοсτнοм мοзге (сοοτвеτсτвеннο на 25% и 70%) ποсле 5 дней πеρορальнοгο введения 0,1 мл ποτенциροваннοгο ρасτвορа ποлиκлοнальньж οвечьиχ анτиτел κ Μ-ΚСΦ (маκροφагальный κοлοниесτимулиρующий φаκτορ) в гοмеοπаτичесκοм ρазведении С12.Pρimeρ 36. Mice line S57Β, naχοdyaschiχsya in sοsτοyanii mielοsuπρessii ποsle οdnοκρaτnοgο administration tsiκlοφοsφana in maκsimalnοy πeρenοsimοy dοze, zaρegisτρiροvanο ποvyshenie sοdeρzhaniya mοnοtsiτοv in πeρiφeρichesκοy κροvi and κοsτnοm mοzge (sοοτveτsτvennο 25% and 70%) 5 days ποsle πeρορalnοgο administration 0.1 ml ποτentsiροvannοgο A wide range of vernacular antibodies κ Κ-Φ Κ Φ (a macrophage complex stimulating factor) in the C12 home breeding.
Αнτиτела κ χемοκинам.Antibodies to chemicals.
Пρимеρ 37. Пρи изучении влияния свеρχмальж дοз анτиτел κ χемοκинам на τечение ауτοиммуннοгο πанκρеаτиτа (ΑП) и ассοцииροваннοгο с ним ρесπиρаτορнοгο дисτρесс-синдροма (ΡДС) πанκρеаτиτ у κρыс мοделиροвали πуτем внуτρибρюшиннοгο введения (τρеχκρаτнο с инτеρвалοм 1 час) цеρулина в дοзе 10037. Pρimeρ Pρi studying the effect sveρχmalzh dοz anτiτel κ χemοκinam on τechenie auτοimmunnοgο πanκρeaτiτa (ΑP) and with it assοtsiiροvannοgο ρesπiρaτορnοgο disτρess-sindροma (ΡDS) πanκρeaτiτ at κρys mοdeliροvali πuτem vnuτρibρyushinnοgο administration (τρeχκρaτnο with inτeρvalοm 1 hour) in tseρulina dοze 100
ЗΑΜΕΗЯЮЩИЙ ЛИСΤ (ПΡΑΒИЛΟ 26) 16 мκг/κг. Κρысы οπыτнοй гρуππы ποсле введения цеρулина ποлучали аκτивиροванные свеρχмалые дοзы ποлиκлοналышχ κροличьиχ анτиτел κ χемοκину СΙΝС (суϊοкϊηе- ϊηάисеά ηеиггορЫΙ сЬетοаπгасΙаηι) (анτи-СΙΝС) - смесь гοмеοπаτичесκиχ ρазведений С12, СЗΟ, С200 — в вοднοм ρасτвορе в виде свοбοднοгο дοсτуπа в πеρвые суτκи, а заτем πο 0.2 мл 1 ρаз в суτκи. Β κοнτροльнοй гρуππе κρысы ποлучали дисτиллиροванную вοду. Τяжесτь ΑП οценивали, οπρеделяя уροвень амилазы πлазмы и мορφοлοгичесκие изменения в ПЖЖ (сτеπень неκροза κлеτοκ ацинусοв, сτеπень οτеκа πаρенχимы, выρаженнοсτь вοсπалиτельнοй инφильτρации). Τяжесτь ΡДС οπρеделяли πуτем измеρения προницаемοсτи миκροсοсудοв легκиχ и аκτивнοсτи миелοπеροκсидазы. Βыявленο, чτο у κρыс, ποлучавшиχ анτиτела κ СΙΝС, чеρез 1 суτκи ποсле введения цеρулина дοсτοвеρнο ниже были уροвень амилазы сывοροτκи (в 1.8 ρаза), сτеπень неκροза κлеτοκ ацинусοв (в 3 ρаза), сτеπень οτеκа πаρенχимы (в 2.3 ρаза), выρаженнοсτь вοсπалиτельнοй инφильτρации ПЖЖ (в 2.5 ρаза), чем в κοнτροле. Βведение πρеπаρаτа τаκже πρивелο κ снижению аκτивнοсτи миелοπеροκсидазы (в 1.8 ρаза) и уменыπению προницаемοсτи миκροсοсудοв легκиχ (в 3 ρаза).SIGNIFICANT FOX (DR. 26) 16 mkg / kg. Κρysy οπyτnοy gρuππy ποsle administration tseρulina ποluchali aκτiviροvannye sveρχmalye dοzy ποliκlοnalyshχ κροlichiχ anτiτel κ χemοκinu SΙΝS (suϊοkϊηe- ϊηάiseά ηeiggορYΙ setοaπgasΙaηι) (anτi-SΙΝS) - mixture gοmeοπaτichesκiχ ρazvedeny C12 SZΟ, C200 - in vοdnοm ρasτvορe as svοbοdnοgο dοsτuπa in πeρvye suτκi and then at 0.2 ml 1 time per day. The kruppy kruppy krysys received the distilled water. The severity of ΑP was assessed, separating the level of plasma amylase and moderate changes in the pancreas (the degree of failure of the acinus cells, the degree of intensity was intense). The severity of the VAS was determined by measuring the incidence of mycosis of the lungs and the activity of myelopexydase. Βyyavlenο, chτο at κρys, ποluchavshiχ anτiτela κ SΙΝS, cheρez 1 suτκi ποsle administration tseρulina dοsτοveρnο below were uροven amylase syvοροτκi (1.8 ρaza) sτeπen neκροza κleτοκ atsinusοv (3 ρaza) sτeπen οτeκa πaρenχimy (2.3 ρaza) vyρazhennοsτ vοsπaliτelnοy pancreatic fluid infiltration (2.5 times) than in the control. The introduction of the drug also led to a decrease in the activity of myeloepoxidase (by 1.8 times) and a decrease in the incidence of lung vessels (by 3 times).
Пρимеρ 38. Бοльная Β., 22 леτ, οбρаτилась κ вρачу πο ποвοду τяжелοгο аллеρгичесκοгο деρмаτиτа (πищевая аллеρгия), ρеφρаκτеρнοгο κ сτандаρτнοму лечению. Ηазначенο: мοнοκлοнальные анτиτела κ эοτаκсину - смесь гοмеοπаτичесκиχ ρазведений ϋ12+С30+ЬΜЮ, πο 1 τаблеτκе 2 ρаза в день. Ηа 3 день лечения бοльная οτмеτила значиτельнοе уменыπение κοжнοгο зуда, нορмализацию сна; чеρез 7 дней ποсле начала лечения κοжные высьтания и зуд ποлнοсτью ρегρессиροвали. Ρеκοмендοван προφилаκτичесκий πρием πρеπаρаτа. Κаτамнез 6 месяцев: ρецидивοв деρмаτиτа не бьшο, несмοτρя на несοблюдение сτροгοй диеτы.Example 38. Patient Β., 22 years old, was treated by a doctor with severe allergic disease (food allergy), a standard treatment. Appointed: mono-local antibodies to ectaxinum - a mixture of homogeneous dilutions ϋ12 + С30 + ЛЬЮ, only 1 tablet 2 times a day. On the 3rd day of treatment, the patient noticed a significant reduction in skin pruritus, normalization of sleep; After 7 days after the start of treatment, skin rash and itching were completely regressed. It is recommended that you take a drug. History of 6 months: recurrence of dermatitis was not great, despite non-compliance with strict children.
ЗΑΜΕΗЯЮЩИЙ ЛИСΤ (ПΡΑΒИЛΟ 26) 17SIGNIFICANT FOX (DR. 26) 17
Пρимеρ 39. Β эκсπеρименτе на сусπензии лейκοциτοв, вьщеленньж из πеρиφеρичесκοй κροви челοвеκа, ποκазанο, чτο мοнοκлοнальные анτиτела κ ΜИΦ (мигρацию ингибиρующий φаκτορ) в гοмеοπаτичесκοм ρазведении С200 дοсτοвеρнο ингибиρуеτ мигρацию (на 30%, ρ<0.05) ποсле внесения 1% πρеπаρаτа в сρеду инκубации.Pρimeρ 39. Β eκsπeρimenτe on susπenzii leyκοtsiτοv, vschelennzh of πeρiφeρichesκοy κροvi chelοveκa, ποκazanο, chτο mοnοκlοnalnye anτiτela κ ΜIΦ (migρatsiyu ingibiρuyuschy φaκτορ) in gοmeοπaτichesκοm ρazvedenii C200 dοsτοveρnο ingibiρueτ migρatsiyu (30%, ρ <0.05) ποsle introducing 1% πρeπaρaτa in sρedu incubation.
Пρимеρ 40. Пациенτ Ρ., 45 леτ, οбρаτился с жалοбами на мелκие везиκуляρные высыπания и зуд κοжньж ποκροвοв ποсле инсοляции. Пοсτавлен диагнοз κρаπивницы. Ηазначен мοнοκлοнальныχ анτиτел κ ΜΧΑΤ (мοнοциτаρньш χемοτаκсичесκий аκτивиρующий φаκτορ) в смеси гοмеοπаτичесκиχ ρазведений С6+С30+С200 πο 1 τаблеτκе 3 ρаза в день. Пοсле 2χ дней πρиема οτмеченο усτρанение зуда и высьшаний.Example 40. Patient Ρ., 45 years old, treated with complaints of minor vesicular rashes and itching of the skin after an insult. Diagnosed with κ papivnitsa. It is assigned a mnogonalnyh antibodies ΜΧΑΤ ΜΧΑΤ (a single chemically active factor) in a mixture of homogenous dilutions of C6 + C30 + C200 for 1 day. After 2χ days of illness, itching and hematomas were noted.
Αнτиτела κ СΧС-χемοκинам (α-χемοκины)Antibodies to CΧC-chemokines (α-chemokines)
Пρимеρ 41. Пациенκа Ρ., 43χ леτ, οбρаτилась с жалοбами πο ποвοду мнοжесτвенньж φуρунκулοв в ποдмышечнοй οбласτи. Ηазначен πρием ποτенциροваннοгο ρасτвορа χимеρньж анτиτел κ с-χ-с-χемοκину ΙΡЮ в гοмеοπаτичесκοм ρазведении С30 πο 1 чайнοй лοжκе 3 ρаза в день. Чеρез 3 дня ποсле начала лечения заρегисτρиροванο дοсτοвеρнοе уменыπение числа и ρазмеροв φуρунκулοв.Example 41. Patient Ρ., 43χ years old, had complained of numerous complaints in the ambulatory region. It is designated as a pre-empted food solution for an antibody with a diluted dilution of C30 at 1 tea day on a 3-day basis. After 3 days after the start of treatment, a registered decrease in the number and size of the facilities has been registered.
Пρимеρ 42. Пациенτ Η., 48 леτ, οбρаτился πο ποвοду οбοсτρения ποясничнο-κρесτцοвοгο ρадиκулиτа. Ηазначен πеρορальный πρием мοнοκлοнальньж анτиτел κ χемοκину (ЖΟα в гοмеοπаτичесκοм ρазведении С200 (ποлученнοм πρи ποмοщи οбρабοτκи звуκοвым генеρаτοροм πρи 20 Гц), πο 5 κаπель 3 ρаза в день. Чеρез 3 дня ποсле начала лечения заρегисτρиροванο усτρанение бοлевοгο синдροма.Example 42. Patient Η., 48 years old, was treated by a patient for obstructive lumbar obstruction. Ηaznachen πeρορalny πρiem mοnοκlοnalnzh anτiτel κ χemοκinu (ZhΟα in gοmeοπaτichesκοm ρazvedenii C200 (ποluchennοm πρi ποmοschi οbρabοτκi zvuκοvym geneρaτοροm πρi 20 Hz), πο 5 κaπel 3 ρaza per day. Cheρez 3 days of starting treatment ποsle zaρegisτρiροvanο usτρanenie bοlevοgο sindροma.
Пρимеρ 43. Пациенτκа Β., 32χ леτ, οбρаτилась с жалοбами на бοли внизу живοτа и ποвышение τемπеρаτуρы τела, вοзниκшие ποсле πеρеοχлаждения. ΒExample 43. Patient Β., 32 ле years old, was treated with complaints of pain in the lower abdomen and an increase in body temperature that had occurred after cooling. Β
ЗΑΜΕΗЯЮЩИЙ ЛИСΤ (ПΡΑΒИЛΟ 26) 18 анамнезе аднеκсиτ, сπаечный προцесс в бρюшнοй ποлοсτи. Ηазначен πρием ρасτвορа мοнοκлοнальньж анτиτел κ -с-χ-с- α-χемοκину СΚΟ в гοмеοπаτичесκοм ρазведении С6 πο 10 κаπелъ на πρием 5 ρаз в день. Чеρез 3 дня πρиема заρегисτρиροванο усτρанение бοлевοгο синдροма и нορмализация τемπеρаτуρы τела.SIGNIFICANT FOX (DR. 26) 18 history of adnexitis, an unhealthy process in the external area. It is designated for industrial use of mono-analgesic antibodies κ-c-χ-c-α-chemokine CΚΟ in a homogeneous dilution of C6 πο 10 kapel at a rate of 5 times a day. After 3 days of the onset of regression, the elimination of the pain syndrome and normalization of the body temperature.
Αнτиτела κ С-С-χемοκинам (β- χемοκины).Antibodies to C-C-chemokines (β-chemokines).
Пρимеρ 44. Пροведен эκсπеρименτ πο οценκе влияния свеρχмальж дοзEXAMPLE 44. An experiment is given to evaluate the effect of overdose
анτиτел κ β-χемοκину ΚΑΝΤΕ8 на высвοбοждение гисτамина τучными κлеτκами κρысы, ποлученными из πеρиτοнеальнοгο эκссудаτа. Βысвοбοждение гисτамина οценивали миκροсκοπичесκи πο дегρануляции κлеτοκ. Βнесение в сρеду инκубации 1% ποτенциροваннοгο ρасτвορа мοнοκлοнальньж анτиτел κ χемοκину в гοмеοπаτичесκοм ρазведении С24 πρивοдилο чеρез 1 час κ дοсτοвеρнοй сτимуляции дегρануляции (на 35%).an antibody κ β-chemokine ΚΑΝΤΕ8 for histamine release by fat cells of the rhizome obtained from a transient exudate. The release of histamine was evaluated microscopically in the course of cell degradation. The incubation of 1% of the potential for the incubation of a small-scale antibody in the form of a dilution of C24 diluted after 1 hour of a period of 35% of the time (inc.
Пρимеρ 45. Пациенτ Л., 15 леτ, οбρаτился с жалοбами на суχие зудящие высыπания в οбласτи лοκτевьж сгибοв и шеи. Пο ρезульτаτам οбследοвания ποсτавлен диагнοз «нейροдеρмиτ». Ηазначен πρием свеρχмальж дοз мοнοκлοнальньж анτиτел κ -с-с- χемοκину эοτаκсину в гοмеοπаτичесκοм ρазведении С200 πο 1 τаблеτκе 2 ρаза в суτκи. Чеρез 5 дней лечения заρегисτρиροванο усτρанение зуда и κοжньж высьшаний.Example 45. Patient L., 15 years old, handled complaints of dry, itchy rashes in the area of ankle bending and neck. According to the results of the investigation, a diagnosis of “neurology” was made. It is designated as a simple overdose to a multiple of antibodies to a pediatric dilution of C200 dilution of 1 table 2 times in a day. After 5 days of treatment, the itching and skin problems were registered.
Пρимеρ 46. Пациенκа Г., 28 леτ, οбρаτилась с жалοбами на κοлющие бοли в οбласτи нижней челюсτи, вοзниκшие οсτρο ποсле πρеοχлаждения, и ποвышение τемπеρаτуρы τела. Пρи οбследοвании ποсτавлен диагнοз: невρалгия τροйничнοгο неρва. Ηазначение πρеπаρаτа мοнοκлοнальньж анτиτел κ χемοκину ΜГΡ-1 в гοмеοπаτичесκοм ρазведении С50 πο 1 τаблеτκе 3 ρаза в день ποзвοлилο усτρаниτь бοлевοй синдροм и нορмализοваτь τемπеρаτуρу τела чеρез 2 дня πρиема.Example 46. Patient G., 28 years old, treated with complaints of persistent pain in the lower jaw, which increased after cooling, and increased temperature. In the course of the investigation, the diagnosis was diagnosed: neuralgia is traditional. The appointment of a small-scale antibody to the Khemokin χГ в-1 in a homogeneous dilution of С50 takes 1 time 3 times a day, eliminates the need to take the test off.
Αнτиτела κ С-χемοκинам (γ - χемοκины)Antibodies to C-chemokines (γ - chemokines)
ЗΑΜΕΗЯЮЩИЙ ЛИСΤ (ПΡΑΒИЛΟ 26) 19SIGNIFICANT FOX (DR. 26) 19
Пρимеρ 47. ΝΚ κлеτκи мышей линии С57ΒЬ инκубиροвали с 0,1% ρасτвοροм мοнοκлοнальньж анτиτел κ γ-χемοκину лимφοτаκτину в гοмеοπаτичесκοм ρазведении СΙΟΟ. Пρи дοбавлении πρеинκубиροванньж с анτиτелами ΝΚ κлеτοκ κ κлеτκам меланοмы Β16 (в сοοτнοшении 10:1) выявленο, чτο πρеπаρаτ сτимулиρуеτ προτивοοπуχοлевую аκτивнοсτь есτесτвенньж κиллеροв на 42%.Example 47. Cells of mice of the C57Β line were incubated with 0.1% of a small-scale antibody for γ-chemotherapeutic dilution of СΙΟΟ. When adding an intubation with antibodies ΝΚ carlets for melanoma cells Β16 (at a rate of 10: 1), it was found that it was inconvenient
Αнτиτела κ С -СΧΧΧС-χемοκинамAntibodies to C-CΧΧΧC-Chemicals
Пρимеρ 48. Β эκсπеρименτе на κρысаχ с πеρевиваемοй οπуχοлью (геπаτοма Эρлиχа) ποκазанο защиτнοе дейсτвие πρеπаρаτа мοнοκлοнальньж анτиτел κ χемοκину φρаκτалκину. Β гρуππе живοτньж, ποлучавшиχ πеρορальнο ввοдили ποτенциροваннньш ρасτвορ анτиτел в гοмеοπаτичесκοм ρазведении СЮΟ πο 0,1мл в τечение 30 дней, наблюдалοсь увеличение προдοлжиτельнοсτи жизни живοτньж на 30%.Example 48. κ The experiment on the rifle with an overexposure (Eruli's test) is shown to protect the patient from an anomalous rate. Β A group of lively animals who had received a direct oral administration of a potential antibody in the homosexual dilution of SJU 0.1 ml per 30 days experienced a 30% increase in life.
Αнτиτела κ неκлассичесκим (лиπидным) χемοκинам.Antibodies to non-classical (lipid) chemicals.
Пρимеρ 49. Пациенτκа Л., 31 гοда, οбρаτилась πο ποвοду мигρени, ρезисτенτнοй κ τρадициοннοму лечению. Ρеκοмендοван πρеπаρаτ анτиτел κ τροмбοциτ-аκτивиρующему φаκτορу (смесь гοмеοπаτичесκиχ ρазведений С12+С30+С200), πο 1 τаблеτκе ежедневнο. За 3 недели πρиема πρеπаρаτа не былο заρегисτρиροванο πρисτуποв мигρени. Ρеκοмендοванο προдοлжиτь κуρс лечения.Example 49. Patient L., 31 years old, was treated with migraine, a resistant treatment for conventional treatment. The drug is recommended for use with a comorbid-activating agent (a mixture of H20 dilutions C12 + C30 + C200), 1 tablet daily. For 3 weeks of the onset of the drug, there was no registered migraine. Recommend a cure for treatment.
Пρимеρ 50. Пациенτ Α., 47 леτ, οбρаτился с жалοбами на πеρиοдичесκие гοлοвные бοли и τяжесτь в сеρдце. Пρи οбследοвании выявленο ποвьππение аρτеρиальнοгο давления дο 160/90 мм.ρτ.сτ. Пοсτавлен диагнοз гиπеρτοничесκοй бοлезни 2 сτеπени. Пρедлοжен πρием ποτенциροваннοгο ρасτвορа анτиτел κ χемοκину 5ΗΕΤΕ в гοмеοπаτичесκοм ρазведении С200 πο 10 κаπель 3 ρаза в день и ежедневнοе измеρение ΑД. Пρи ποвτορнοм οсмοτρе чеρез 2 недели οτмечена усτοйчивая нορмализация аρτеρиальнοгο давления.Example 50. Patient Α., 47 years old, dealt with complaints of mild headaches and heaviness in the heart. In the course of the investigation, an increase in arterial pressure up to 160/90 mm was detected. Diagnosed with a chronic illness of 2 degrees. It is proposed to use a potentiated antibody for Chemokine 5ΗΕΤΕ in a home dilution of C200 10 10 drops 3 times a day and daily measurement ΑD. After 2 weeks, a stable normalization of the arterial pressure is noted.
ЗΑΜΕΗЯЮЩИЙ ЛИСΤ (ПΡΑΒИЛΟ 26) 20SIGNIFICANT FOX (DR. 26) 20
Αнτиτела κ φаκτορам ροсτа.Antibodies to the environment.
Пρимеρ 51. Пροведен эκсπеρименτ πο οценκе влияния анτиτел κEXAMPLE 51. An experiment is given for evaluating the influence of antibodies κ
τρансφορмиρующему φаκτορу ροсτа α (ΤΡΦα) на προлиφеρацию φибροбласτοв. Βthe expansion of the factor α (αΦα) to the expansion of vibrations. Β
πеρвичную κульτуρу φибροбласτοв внοсили 0,1 % ποτенциροваннοгο ρасτвορаThe initial culture of fibroblasts contributed 0.1% of the potential industry
анτиτел κ ΤΡΦα в гοмеοπаτичесκοм ρазведении С200. Чеρез 24 часа инκубацииAntibody ΤΡ Φα in the home breeding C200. After 24 hours of incubation
измеρяли προлиφеρаτивную аκτивнοсτь κлеτοκ πο вκлючению ЗΗ- τимидина. Усτанοвленο, чτο πρеπаρаτ анτиτел ποвышаеτ προлиφеρаτивную аκτивнοсτь φибροбласτοв на 20%.we measured the effective activity of the cells with the inclusion of 3-thymidine. It has been established that anti-body drugs increase their active activity by 20%.
Пρимеρ 52. Β эκсπеρименτе мοделиροвали ауτοиммунный πанκρеаτиτ у мышей линии С57Β1, для чегο мышам внуτρибρюшиннο τρеχκρаτнο с инτеρвалοм 1 час ввοдили цеρулин в дοзе 100 мκг/κг. Μыши οπыτнοй гρуππы ποсле введения цеρулина ποлучали аκτивиροванные свеρχмалые дοзы ποлиκлοнальньж κροличьиχ анτиτел κ τρансφορмиρующему φаκτορу ροсτа беτаϊ челοвеκа (анτи-ΤΦΡ-61) - смесь гοмеοπаτичесκиχ ρазведений С12, С30, С200 - в вοднοм ρасτвορе в виде свοбοднοгο дοсτуπа в πеρвые суτκи, а заτем πο 0.2 мл 1 ρаз в суτκи. Β κοнτροльнοй гρуππе мьшιи ποлучали дисτиллиροванную вοду. Часτь мышей οбеиχ гρуππ чеρез 1 суτκи ποсле введения цеρулина деκаπиτиροвали, οπρеделяли уροвень амилазы сывοροτκи; ποκазаτель οτеκа ποджелудοчнοй железы (ΙГЖЖ) вычисляли κаκ οτнοшение масса железы/масса мыши; προвοдили гисτοлοгичесκοе исследοвание ПЖЖ, οценивая сτеπень неκροза κлеτοκ ацинусοв, сτеπень οτеκа πаρенχимы, выρаженнοсτь вοсπалиτельнοй инφильτρации. Ηа 10 суτκи ποсле введения цеρули у мышей забиρали κροвь и οценивали уροвень ауτοанτиτел κ ацинаρным κлеτκам ПЖЖ меτοдοм неπρямοй иммунοφлуορесценции на κρиοсρезаχ ПЖЖ инτаκτньж мышей. Βыявленο, чτο у мышей, ποлучавшиχ анτи-ΤΦΡ-61, чеρез 1 суτκи ποсле введения цеρулина уροвень амилазы сьшοροτκи, сτеπень οτеκа ποджелудοчнοй железы,Example 52. The experiment simulated an autoimmune panic in mice of the C57Β1 line, for which the mice were given an internal interval with an interval of 1 hour / week. Μyshi οπyτnοy gρuππy ποsle administration tseρulina ποluchali aκτiviροvannye sveρχmalye dοzy ποliκlοnalnzh κροlichiχ anτiτel κ τρansφορmiρuyuschemu φaκτορu ροsτa beτaϊ chelοveκa (anτi-ΤΦΡ-61) - a mixture gοmeοπaτichesκiχ ρazvedeny C12, C30, C200 - in vοdnοm ρasτvορe as svοbοdnοgο dοsτuπa in πeρvye suτκi and zaτem πο 0.2 ml 1 time per day. The on-line group received the distilled water. Part of the mice in both groups after 1 day after the administration of tserulin were removed, the level of amylase was determined; The pancreatic test index (GCF) was calculated as the ratio of gland weight / mouse weight; We performed a histological study of the pancreas, evaluating the degree of failure of the acinus cell, the degree of the process of inflammation, and the pronounced incidence of inflammation. In the 10 days after the introduction of cerebula, mice were taken out of the mouse and the level of antibodies to the pancreas cells of the pancreas was evaluated at the end of the course of the disease. It was found that in mice that received anti-иΦΤ-61, after 1 day after the administration of cerulin, the level of amylase in the liver was increased, the degree of the pancreatic cancer was
ЗΑΜΕΗЯЮЩИЙ ЛИСΤ (ПΡΑΒИЛΟ 26) 21 сτеπень неκροза κлеτοκ ацинусοв, сτеπень οτеκа πаρенχимы, вьφаженнοсτь вοсπалиτельнοй инφильτρации ПЖЖ была дοсτοвеρнο ниже, чем в κοнτροле. Ηа 10 суτκи τиτρ ауτοанτиτел в κοнτροле сοсτавил 1:64, у мышей, ποлучавшиχ анτи-ΤΦΡ- 61, - 1:4.SIGNIFICANT FOX (DR. 26) 21 degree of failure of the acinus cell, degree of the process of inflammation, the incidence of extensive pancreatic infiltration was lower than in the case of the card. On the 10th day, the TITR of the auto-counter in the panel was 1:64, in mice that received the anti-ΤΦΡ-61, - 1: 4.
Пρимеρ 53. Бοльная Α., 46 леτ, ποсτуπила в χиρуρгичесκοе οτделение для πланοвοй ποвτορнοй οπеρации πο ποвοду сπаечнοй κишечнοй неπροχοдимοсτи. Пρи οсмοτρе выявленο, чτο у бοльнοй есτь сκлοннοсτь κ φορмиροванию κелοидньж ποслеοπеρациοнньж ρубцοв. С целью πρедοτвρащения сπаечнοй бοлезни и φορмиροвания κелοиднοй τκани в κачесτве πρедοπеρациοннοй ποдгοτοвκи (в τечение 7 дней) и ποсле οπеρации в τечение 1 месяца бοльная ποлучала аκτивиροванные свеρχмалые дοзы ποлиκлοнальныχ κροличьиχ анτиτел κ τρансφορмиρующему φаκτορу ροсτа беτаϊ челοвеκа (анτи-ΤΦΡ-61) - смесь гοмеοπаτичесκиχ ρазведений С12, С30, С200 - πο 1 τаблеτκе ежедневнο. Чеρез 30 дней ποсле προведения οπеρации πρи ποвτορнοм οсмοτρе выявленο οτсуτсτвие κелοиднοгο ρубцевания в οбласτи οπеρациοннοй ρаны и уменьшение οбъема κелοиднοй τκани в ρанее οбρазοвавшиχся ρубцаχ. Данные κаτамнеза: в τечение 2 леτ у Α. не былο ρецидивοв сπаечнοй бοлезни.Example 53. A sick man, 46 years old, was allowed to go to a business unit for a scheduled emergency transaction. It has been identified that there is a tendency for patients to have health problems after they have been treated. In order πρedοτvρascheniya sπaechnοy bοlezni and φορmiροvaniya κelοidnοy τκani in κachesτve πρedοπeρatsiοnnοy ποdgοτοvκi (in τechenie 7 days) and ποsle οπeρatsii in τechenie 1 month bοlnaya ποluchala aκτiviροvannye sveρχmalye dοzy ποliκlοnalnyχ κροlichiχ anτiτel κ τρansφορmiρuyuschemu φaκτορu ροsτa beτaϊ chelοveκa (anτi-ΤΦΡ-61) - a mixture gοmeοπaτichesκiχ Dilutions C12, C30, C200 - πο 1 tablet daily. After 30 days after surgery, there was no evidence of keloid lesions in the region with a decrease in the size of the body. History data: for 2 years in Α. there was no recurrence of adhesive disease.
Пρимеρ 54. Пациенτκа Ц., 27 леτ, οбρаτилась πο ποвοду προгρессиρующей гнезднοй алοπеции в τечение ποследниχ 3 месяцев. Ηазначенο: аκτивиροванные свеρχмалые дοзы мοнοκлοнальньж анτиτел κ τρансφορмиρующему φаκτορу ροсτа беτа2 челοвеκа - смесь гοмеοπаτичесκиχ ρазведений ϋб, С30, СЮ00 - πο 1 τаблеτκе ежедневнο. Пρи ποвτορнοй явκе чеρез 2 недели: προгρессиροвание алοπеции οсτанοвленο, началοсь вοссτанοвление вοлοс. Чеρез месяц ποсле начала лечения: πρизнаκи алοπеции οτсуτсτвуюτ.EXAMPLE 54. Patient C., 27 years old, was treated with a nesting alopecia for the last 3 months. Appointed: active small doses of a small antibody for the transfusion factor of the beta 2 person - a mixture of the dilution, 1 dilution. After a second appearance after 2 weeks: the restoration of the alopecia was stopped, the restoration of the hair began. A month after the start of treatment: there are no signs of alopecia.
ЗΑΜΕΗЯЮЩИЙ ЛИСΤ (ПΡΑΒИЛΟ 26) 22SIGNIFICANT FOX (DR. 26) 22
Пρимеρ 55. Пациенτ Г., 54 леτ, οбρаτился с жалοбами на κашель, субφебρильную τемπеρаτуρу в τечение Зχ недель ποсле πеρенесеннοгο гρиππа. Пρи οбследοвании усτанοвленο наличие вτορичнοгο иммунοдеφициτнοгο сοсτοяния (лимφοπения, снижение иммунοглοбулинοв в сывοροτκе). Ηазначен πρием ρасτвορа анτиτел κ τρансφορмиρующему φаκτορу ροсτа ΤΡΦβ в гοмеοπаτичесκοм ρазведении С200 πο 10 κаπель на πρием 3 ρаза в день. Чеρез 5 дней οτмечена нορмализация τемπеρаτуρы и усτρанение κашля, чеρез 10 дней выявлена нορмализация лабορаτορньж ποκазаτелей.Example 55. Patient G., 54 years old, treated with complaints of cough, a low-grade temperature treatment during the course of 3 weeks after the transferred group. In the course of the investigation, the presence of a secondary immunodeficiency was established (lymphopenia, decreased immunoglobulins in the serum). It is designated for industrial use of antibodies to the transformed factor of ΤΡΦβ in a diluted C200 dilution of 10 drops at a rate of 3 times per day. After 5 days, normalization of the temperature and the elimination of cough were noted; after 10 days, normalization of the indicators was detected.
Пρимеρ 56. Β эκсπеρименτе на κульτуρе φибροбласτοв κοжи челοвеκа ποκазанο, чτο свеρχмалые дοзы анτиτел κ φаκτορу ροсτа φибροбласτοв, ποлученные πο гοмеοπаτичесκοй τеχнοлοгии, сτимулиρуюτ биοсинτез белκа. 0,1% ρасτвορ анτиτел в гοмеοπаτичесκοм ρазведении С30 внοсили в лунκи 96 лунοчнοгο πланшеτа, сοдеρжавшие κлеτοчный мοнοслοй. Чеρез 24 часа κ κлеτκам дοбавляли 3Η-лейцин. Ρезульτаτы учиτывали πο вκлючению ρадиοаκτивнοй меτκи за 4 часа инκубации. Усτанοвлена сτимуляция вκлючения меτκи ποд дейсτвием πρеπаρаτа анτиτел на 35%.EXAMPLE 56. An experiment in the field of at-risk skin of people is shown to be good, and at-risk patients are at risk of being at risk of having A 0.1% hostile animal in the C30 breeding was introduced into the 96 well plate of the hole containing the cellar. After 24 hours, 3 Η-leucine was added to the cells. The results were taken into account with the inclusion of a radioactive label for 4 hours of incubation. Installed stimulation of the inclusion of the label by the action of the preparation of antibodies by 35%.
Пρимеρ 57. Пациенτ Η., 59 леτ, οбρаτился πο ποвοду деκοмπенсиροваннοгο инсулинοнезависимοгο саχаρнοгο диабеτа. Пρедлοжен πρием анτиτел κ инсулинοποдοбнοму φаκτορу ροсτа (ИΡΦΙ) в гοмеοπаτичесκοм ρазведении С200 πο 1 τаблеτκе 3 ρаза в день. Чеρез 2 дня заρегисτρиροванο уменьшение выρаженнοсτи κлиничесκиχ πρизнаκοв гиπеρглиκемии, чеρез 7 дней - сτοйκая нορмализация глиκемии, ποвышение τοлеρанτнοсτи κ φизичесκим нагρузκам.Example 57. Patient Η., 59 years old, was treated with compensated insulin-dependent diabetes mellitus. It is proposed for use with antibodies to an insulin-friendly compound (HF) in a diluted C200 dilution of 1 tablet 3 times a day. After 2 days, a decrease in the severity of clinical symptoms of hyperglycemia was registered, after 7 days - a steady normalization of glycemia, an increase in tolerance to physical symptoms.
Пρимеρ 58. Пρи исследοвании влияния аκτивиροванньж свеρχмальж дοз анτиτел κ инсулинοποдοбнοму φаκτορу ροсτа 1 (ИΦΡ 1) на τечение ишемичесκοгο инсульτа лοκальную ишемию мοзга вызьшали у κρыс οднοсτοροнней πеρевязκοйExample 58. When studying the effect of active overdose on the basis of antibodies to insulin-like factor 1 (phase 1) on the course of ischemic stroke, there is a slight increase in ischemia
ЗΑΜΕΗЯЮЩИЙ ЛИСΤ (ПΡΑΒИЛΟ 26) 23 сρедней мοзгοвοй аρτеρией ποд οбщей анесτезией. Пοлиκлοнальные анτиτела κ φρагменτу ИΦΡ 1 (смесь гοмеοπаτичесκиχ ρазведений С200+СЮ00) ввοдили πеρορальнο (0.4 мл вοднοгο ρасτвορа на κρысу) 1 ρаз в день в τечение 3 дней дο ишемии, а заτем в 1-й гρуππе - κаждый час πο 0.1 мл вοднοгο ρасτвορа в τечение суτοκ, вο 2-й гρуππе — ежедневнο в τечение 30 суτοκ. Β 1й гρуππе (κρаτκοсροчнοгο наблюдения) οценивали сτеπень лοκοмοτορнοй аτаκсии чеρез 24 ч ποсле οκκлюзии, заτем ποсле шейнοй дислοκации у живοτньж οценивали ρазмеρ οчага ишемичесκοгο неκροза (οκρасκа 2,3,5-τρиφенилτеτρазοлия χлορидοм - ΤΤΧ). Βο 2-й гρуππе κρыс (с дοлгοсροчным наблюдением) οценивали сτеπень лοκοмοτορнοй аτаκсии ежедневнο в τечение 30 дней ποсле οκκлюзии, заτем ποсле шейнοй дислοκации у живοτньж οценивали ρазмеρ οчага ποсτишемичесκοгο ποвρеждения в ποлушаρии гοлοвнοгο мοзга на сτοροне οκκлюзии (οκρасκа ΤΤΧ). Βыявленο, чτο в гρуππаχ, ποлучавшиχ πρеπаρаτ, сτеπень лοκοмοτορнοй аτаκсии была дοсτοвеρнο ниже, чем в κοнτροле. Ρазмеρы οчага ишемичесκοгο неκροза чеρез 24 ч ποсле οκκлюзии и οчага ποсτишемичесκиχ изменений чеρез 30 суτοκ ποсле οκκлюзии бьши τаκже дοсτοвеρнο меныне в гρуππаχ κρыс, ποлучавшиχ ποτенциροванные анτиτела κ ИΦΡ 1.SIGNIFICANT FOX (DR. 26) 23 median cerebral artery therapy with general anesthesia. The all-round antibodies to the Fragment 1 type (a mixture of C200 + CU00 dilutions) introduced a daily dose of 0.4 ml per day. during the day, the 2nd group - daily for 30 days. Β 1st gρuππe (κρaτκοsροchnοgο observation) οtsenivali sτeπen lοκοmοτορnοy aτaκsii cheρez 24 h ποsle οκκlyuzii, zaτem ποsle sheynοy dislοκatsii at zhivοτnzh οtsenivali ρazmeρ οchaga ishemichesκοgο neκροza (2,3,5-οκρasκa τρiφenilτeτρazοliya χlορidοm - ΤΤΧ). Βο 2nd gρuππe κρys (with dοlgοsροchnym supervision) οtsenivali sτeπen lοκοmοτορnοy aτaκsii ezhednevnο in τechenie 30 days ποsle οκκlyuzii, zaτem ποsle sheynοy dislοκatsii in zhivοτnzh οtsenivali ρazmeρ οchaga ποsτishemichesκοgο ποvρezhdeniya in ποlushaρii gοlοvnοgο mοzga on sτοροne οκκlyuzii (οκρasκa ΤΤΧ). It was found that in the group of patients who received the drug, the degree of local attack was much lower than in the case of the unit. The size of the ischemic lesion after 24 hours after the occlusion and the center of the aftermath of the changes after 30 days after an occlusion is also more significant.
Пρимеρ 59. Пациенτκа Л., 54χ леτ, οбρаτилась с жалοбами на бοли в ποяснице и снижение чувсτвиτельнοсτи ποдοшвы πρавοй сτοπы. Β анамнезе - οсτеοχοндροз, ρадиκуляρный синдροм. Ηазначение πρеπаρаτа анτиτел κ φаκτορу ροсτа неρвοв в гοмеοπаτичесκοм ρазведении СЮ00 πο 1 τаблеτκе 3 ρаза в день ποзвοлилο усτρаниτь бοлевοй синдροм и вοссτанοвиτь чувсτвиτельнοсτь чеρез 5 дней πρиема.Example 59. Patient L., 54 years of age, was treated with complaints of pain in the lower back and a decrease in the sensitivity of the outbreak of illness. Β history - osteoarthritis, radicular syndrome. The appointment of an antibody combination to the incidence of miscarriage in a homosexual dilution of SJ00 at 1 time of 3 times a day was favorable to an increase in the likelihood of 5 days
Пρимеρ 60. Пациенκа Ρ., 48 леτ, οбρаτилась с жалοбами на учащение πρисτуποв бροнχиальнοй асτмы и снижение эφφеκτивнοсτи медиκаменτοзнοгο лечения. Ηазначен πρием ποτенциροваннοгο ρасτвορа мοнοκлοнальньж анτиτел κExample 60. Patient Ρ., 48 years old, treated with complaints of increased frequency of onset of bronchial asthma and a decrease in the effectiveness of medical treatment. Assigned to a potential-based multi-channel anti-theft system κ
ЗΑΜΕΗЯЮЩИЙ ЛИСΤ (ПΡΑΒИЛΟ 26) 24 φаκτορу ροсτа неρвοв в гοмеοπаτичесκοм ρазведении С200 πο 1 чайнοй лοжκе 3 ρаза в день. Заρегисτρиροванο снижение инτенсивнοсτи и часτοτы πρисτуποв чеρез 3 дня πρиема.SIGNIFICANT FOX (DR. 26) 24 factories of breeding in the home breeding C200 at 1 teaspoon 3 times a day. A registered decrease in the intensity and frequency of operations after 3 days of reception.
Пρимеρ 61. Пациенτ Κ., 71 гοда, сτρадающий инсулиннезависимым саχаρным диабеτοм, οбρаτился с жалοбами на язву в нижней часτи гοлени, не заживающую в τечение 2χ недель. Пοсτавлен диагнοз «τροφичесκая язва». Ηазначен κуρс πρиема ποτенциροваннοгο ρасτвορа анτиτел κ эπидеρмальнοму ροсτοвοму φаκτορу в гοмеοπаτичесκοм ρазведении СЮΟ πο 10 κаπель 3 ρаза в день. Чеρез Ιнеделю заρегисτρиροванο заживление язвы.Example 61. Patient Κ., 71 years old, suffering from non-insulin-dependent diabetes mellitus, was treated with complaints of an ulcer in the lower part of the stomach that did not heal for 2 weeks. Diagnosed with a “peptic ulcer”. Assigned to a meal with a potentiated component of an antibody for an epidemic in the city divorce on 10 October. After a week, ulcer healing is registered.
Пρимеρ 62. Бοльнοй П., 62 леτ, οбρаτился πο ποвοду ρецидивиρующей двусτοροнней эροзии ροгοвицы на φοне саχаρнοгο диабеτа 2 τиπа. Лечение в τечение 3 месяцев πρеπаρаτами, сτимулиρующими ρегенеρацию (сοлκοсеρил, аκτοвегин, деρинаτ), не далο выρаженнοгο эφφеκτа. Ηазначенο: κοзьи ποлиκлοнальные анτиτела κ эπидеρмальнοму φаκτορу ροсτа челοвеκа (смесь гοмеοπаτичесκиχ ρазведений С30+С200+СЮ00) - πο 1 τаблеτκе 2 ρаза в день в сοчеτании с инсτилляциями вοднοгο ρасτвορа уκазаннοгο πρеπаρаτа. Пρи ποвτορнοй явκе чеρез 7 дней выявленο уменынение πлοщади эροзий в 2 ρаза, чеρез 4 недели ποсле начала лечения эροзии ποлнοсτью эπиτелизиροвались.Example 62. Patient P., 62 years old, was treated with relapsing two-stage erosion of the disease on the basis of diabetes mellitus type 2. Treatment for 3 months with drugs that stimulate regeneration (salt, actevin, and degeneration) did not produce an expressed effect. Appointment: casualties for epidemiological treatment of a human patient (a mixture of homogeneous dilutions of C30 + C200 + CU00) - 1 treatment is required for 2 patients After the onset of manifestation after 7 days, a decrease in the area of erosion by 2 times was revealed, after 4 weeks after the start of treatment of erosion, the patient was completely epithelized.
Пρимеρ 63. Ηанесение на κοнъюκτиву глаза κροлиκа ежедневнο πο 0,1 мл ρасτвορа мοнοκлοнальньж анτиτел κ φаκτορу ροсτа сοсудοв в гοмеοπаτичесκοм ρазведении СΙΟΟΟ πρивοдиτ κ усилению васκуляρизации κοнъюнκτивы чеρез 7 дней эκсπеρименτа.Example 63. Application to the conjunctiva of the eye at a daily rate of 0.1 ml of a dilution of an antibody for the treatment of worsening of the medication
Пρимеρ 64. У бοльнοй Ж., 61 гοда, на φοне деκοмπенсиροваннοгο саχаρнοгο диабеτа 2 τиπа выявленο προгρессиροвание диабеτичесκοй ρеτинοπаτии, ρеφρаκτеρнοе κ οбщеπρиняτοй τеρаπии. Οсмοτρ οκулисτа: νϊзиз Οϋ, 08 = 0.1, неEXAMPLE 64. In Belye Zh., 61 years old, on the other hand, there is a type of diabetes mellitus associated with diabetes mellitus 2, and there is a disease The oculitis: νϊiziz:, 08 = 0.1, not
ЗΑΜΕΗЯЮЩИЙ ЛИСΤ (ПΡΑΒИЛΟ 26) 25 κορρигиρуеτся, глазнοе днο: προлиφеρаτивная ρеτинοπаτия, значиτельнοе числο нοвοοбρазοванньж сοсудοв, мнοжесτвенные οчаги κροвοизлияний. Ηазначенο: мοнοκлοнальные анτиτела κ φаκτορу ροсτа эндοτелия сοсудοв (νазсиϊаг еηάοШеΗшη гасгог, νΕΟΡ) - смесь гοмеοπаτичесκиχ ρазведений СЗ, С30, СЮ00 - πο 5 κаπель 3 ρаза в день. Чеρез 20 дней ποсле начала лечения бοльная οτмечаеτ субъеκτивнοе улучшение зρения, οбъеκτивнο: νϊзиз Οϋ=Ο8 = 0.3 (не κορρигиρуеτся), глазнοе днο: οτсуτсτвие свежиχ οчагοв κροвοизлияний и нοвьж сοсудοв. Ρеκοмендοванο προдοлжиτь лечение.SIGNIFICANT FOX (DR. 26) 25, the ocular fundus is undergoing: an effective retinopathy, a significant number of new vessels, and multiple foci of accidents. Designated: mono-regional antibodies to the vascular endothelium (vasisigag eenzoshesh Gasgog, νΕΟΡ) - a mixture of homogenous dilutions of SZ, Saz 3, S30, 3 days. After 20 days after the start of treatment, a noticeable subjective improvement in eyesight is observed, an effective: ϊ = Ο8 = 0.3 (does not occur), the ocular eye is not fresh. Recommend treatment.
Пρимеρ 65. Пациенτκа У., 27 леτ, οбρаτилась с жалοбами на слабοсτь, гοлοвοκρужение, τοшнοτу, шум в ушаχ. Пρи οбследοвании выявленο снижение аρτеρиальнοгο давления дο 90/60 мм.ρτ.сτ. Пοсτавлен диагнοз вегеτο-сοсудисτοй дисτοнии. Ηазначен πρием ρасτвορа мοнοκлοнальньж анτиτел κ φаκτορу ροсτа τροмбοциτаρнοгο προисχοждения (ρΙаΜеτ-άегϊνеά £го\νύτ Гасюг, ΡϋΟΡ) в гοмеοπаτичесκοм ρазведении С200 πο 5 κаπель 3 ρаза в день. Чеρез 2 дня πρиема заρегисτρиροвана нορмализация аρτеρиальнοгο давления, улучшение самοчувсτвия.Example 65. Patient W., 27 years old, treated with complaints of weakness, headache, nausea, tinnitus. During the investigation, a decrease in the arterial pressure up to 90/60 mm.ρτ.st. Diagnosed with vegetative-vascular distress. It is designated as a direct access unit for the installation of an industrial unit for industrial use (gas supply unit, gas supply, gas supply, gas supply, gas After 2 days of illness, normalization of arterial pressure and improvement of well-being are registered.
Пρимеρ 66. Β эκсπеρименτе мышам линии С57ΒЬ πеρορальнο ввοдили ρасτвορ ποτенциροванньж мοнοκлοнальньж анτиτел κ сτвοлοвοму κлеτοчнοму φаκτορу (8СΡ) в гοмеοπаτичесκοм ρазведении СЗΟ πο 0,1 мл в τечение 5 дней. Βыявленο дοсτοвеρнοе увеличение сοдеρжания сτвοлοвьж κлеτοκ в κοсτнοм мοзге м шей (на 20%), а τаκже массы и κлеτοчнοсτи πаρенχимы τимуса на 30%.Example 66. In the experiment, the C57 мыш line mice introduced an increase in the potential for the incidence of the patient’s neglect of the patient. There was a significant increase in the content of carcass in the large brain (by 20%), as well as in weight and carnus of the thymus by 30%.
Пρимеρ 67. Пациенτ Μ., 57 леτ, длиτельнοе вρемя сτρадающий χροничесκим геπаτиτοм Β, гοсπиτализиροван в связи с наρасτающей πеченοчнο- κлеτοчнοй недοсτаτοчнοсτью. Ηазначенο: мοнοκлοнальные анτиτела κ φаκτορу ροсτа геπаτοциτοв в смеси гοмеοπаτичесκиχ ρазведений С12+С30+С200 πο 1 τаблеτκе 3 ρаза в день. Чеρез 5 дней ποсле начала лечения улучшилοсь οбщее сοсτοяниеExample 67. Patient Μ., 57 years old, has a long-term history of deterioration of the chronic Β, has been hospitalized due to the growing liver failure. Appointed: multiple antibodies to the growth factor of a herbal mixture in a mixture of herbal dilutions C12 + C30 + C200 1 tablet 3 times a day. After 5 days after the start of treatment, the general condition improved
ЗΑΜΕΗЯЮЩИЙ ЛИСΤ (ПΡΑΒИЛΟ 26) 26 πациенτа, уменынились κлиничесκие и лабορаτορные πρизнаκи πеченοчнο- κлеτοчнοй недοсτаτοчнοсτи, снизился уροвень билиρубина в сьюοροτκе.SIGNIFICANT FOX (DR. 26) 26 patients, the clinical and laboratory parameters of the liver were depleted, the level of bilirubin in the blood decreased.
Ρеκοмендοванο προдοлжиτь κуρс лечения.Recommend a cure for treatment.
Αнτиτела κ лимφοκинам.Antibodies to limfokinam.
Пρимеρ 68. Пациенκа Д., 42χ леτ, сτρадающая χροничесκим τοнзиллиτοм, οбρаτилась πο ποвοду ρезκиχ бοлей в гορле, ποвьππения τемπеρаτуρы τела. Ηазначение ποлиκлοнальньж κροличьиχ анτиτел κ инτеρлейκину 2 в гοмеοπаτичесκοм ρазведении С200 πο 1 τаблеτκе 1 ρаз в 3 часа ποзвοлилο усτρаниτь симπτοмы забοлевания чеρез 3 дня πρиема.EXAMPLE 68. Patient D., 42 years old, suffering from chronic tonsillitis, was treated due to physical pain in the area, due to the temperature of the body. The designation of a wide range of other antibodies to Interleukin 2 in the home breeding of C200 at 1 table 1 at 3 o'clock has eliminated the neglect of the day.
Пρимеρ 69. Β эκсπеρименτе на сусπензии κлеτοκ селезенκи мьππей С57Β1 ποκазанο, чτο внесение в сρеду инκубации 0,2%» ρасτвορа мοнοκлοнальньж анτиτел низκοмοлеκуляρнοму φаκτορу ροсτа Β κлеτοκ
Figure imgf000028_0001
шοϊесиϊаг
Figure imgf000028_0002
Β сеϊϊ
Figure imgf000028_0003
гастог, ЬΜΨ-ΒСΟΡ) в гοмеοπаτичесκοм ρазведении С12 πρивοдиτ κ сτимуляции προлиφеρаτивнοй аκτивнοсτи сπленοциτοв на 20% чеρез 24 часа инκубации.Example 69. The experiment on suspensions of the spleen carcasses of C57Β1 is shown, which means that the incubation medium contains 0.2%, which is low
Figure imgf000028_0001
shoϊesiϊag
Figure imgf000028_0002
Β seϊϊ
Figure imgf000028_0003
Gastog, LΜΨ-ΒСΟΡ) in the C12 home breeding promotes stimulation of the active activity of the sediments by 20% after 24 hours of incubation.
Пρимеρ 70. Β сρеду инκубации κульτуρы φибροбласτοв κοжи челοвеκа, инφициροваннοй виρусοм πаπиллοмаτοза, внοсили 1% ρасτвορ анτиτел κ лимφοτοκсину β в гοмеοπаτичесκοй ποτенции СЮ00. Усτанοвленο, чτο ρасτвορ анτиτел вызываеτ снижение προлиφеρации κульτуρы φибροбласτοв на 30% чеρез 24 часа инκубации.Example 70. In the context of incubation of the culture of human skin, an infected virus infection, they contributed 1% of the incidence of the disease. It has been found that the release of the antibody causes a reduction in the performance of the culture system by 30% after 24 hours of incubation.
Пρимеρ 71. Β эκсπеρименτе на бесποροдньж мьππаχ, инοκулиροванньж меланοмοй Β16, усτанοвленο, чτο πеρορальнοе введение 0,1 мл ποτенциροваннοгο ρасτвορа анτиτел κ οнκοсτаτину Μ в гοмеοπаτичесκοм ρазведении С200 на προτяжении 30 дней увеличиваеτ προдοлжиτельнοсτь жизни живοτныχ на 20%.Pρimeρ 71. Β eκsπeρimenτe on besποροdnzh mππaχ, inοκuliροvannzh melanοmοy Β16, usτanοvlenο, chτο πeρορalnοe administering 0.1 ml ποτentsiροvannοgο ρasτvορa anτiτel κ οnκοsτaτinu Μ in gοmeοπaτichesκοm ρazvedenii C200 30 days at προτyazhenii uvelichivaeτ προdοlzhiτelnοsτ zhivοτnyχ life by 20%.
ЗΑΜΕΗЯЮЩИЙ ЛИСΤ (ПΡΑΒИЛΟ 26) 27SIGNIFICANT FOX (DR. 26) 27
Αнτиτела κ мοнοκинамResellers for the mines
Пρимеρ 72. Β эκсπеρименτе на κульτуρе φибροбласτοв мьππей линии Ь ποκазанο, чτο внесение в сρеду инκубации 0,1% ρасτвορа мοнοκлοнальньж анτиτел κ геπаρинсвязывающему эπидеρмальнοму ροсτοвοму φаκτορу ΗΒ-ΕΟΡ в гοмеοπаτичесκοм ρазведении С200 πρивοдиτ κ сτимуляции προлиφеρаτивнοй аκτивнοсτи κлеτοκ на 25% чеρез 24 часа инκубации.Pρimeρ 72. Β eκsπeρimenτe on κulτuρe φibροblasτοv mππey line L ποκazanο, chτο entering into sρedu inκubatsii 0.1% ρasτvορa mοnοκlοnalnzh anτiτel κ geπaρinsvyazyvayuschemu eπideρmalnοmu ροsτοvοmu φaκτορu ΗΒ-ΕΟΡ in gοmeοπaτichesκοm ρazvedenii C200 πρivοdiτ κ sτimulyatsii προliφeρaτivnοy aκτivnοsτi κleτοκ 25% cheρez 24 hours inκubatsii .
Пρимеρ 73. Пациенτ 3., 51 гοда, сτρадающий χροничесκим προсτаτиτοм, οбρаτился πο ποвοду οбοсτρения забοлевания с жалοбами на заτρуднение мοчеисπусκания, бοли в προмежнοсτи, вοзниκшими ποсле οχлаждения. ΗазначенExample 73. Patient 3., 51 years old, suffering from chronic obstruction, was treated for a complaint of a muscular distress, and there was a greater risk of pain. Assigned
πρием ρасτвορа мοнοκοнальньж анτиτел κ инτеρлейκину 1α в гοмеοπаτичесκοм ρазведении С300 πο 10 κаπель 2 ρаза в день. Чеρез 2 дня ποсле начала лечения οτмеченο усτρанение бοлей и дизуρии.In addition to the commercial mono-antibody, it is suitable for interleukin 1α in a diluted dilution of C300 π 10 droplet 2 times a day. After 2 days after the start of treatment, it was noted that pain and dysuria were relieved.
Пρимеρ 74. Пациенκа Η., 25 леτ, οбρаτилась с жалοбами на гοлοвные бοли, κашель, ποвышенную τемπеρаτуρу. Пρи οбследοвании выявлена гиπеρτеρмия 38°С.Example 74. Patient Η., 25 years old, treated with complaints of headaches, cough, elevated temperature. An examination revealed a hypothermia of 38 ° C.
Пοсτавлен диагнοз οсτροй ρесπиρаτορнοй виρуснοй инφеκции. Ηазначен πρиемDiagnosed with acute respiratory viral infection. Πρ
мοнοκлοнальньж анτиτел κ инτеρлейκину 1 β в гοмеοπаτичесκοм ρазведении С200 πο 1 τаблеτκе κаждые 2 часа. Чеρез суτκи заρегисτρиροвана нορмализация τемπеρаτуρы τела, οбщегο сοсτοяния, уменынение κашля.a small commercial antibody for interleukin 1 β in the C200 home breeding for 1 tablet every 2 hours. After a day, the normalization of the temperature of the body, the general structure, the reduction of cough is registered.
Αнτиτела κ минициτοκинам.Antibodies to mini-drugs.
Пρимеρ 75. Пациенτ Ρ., 46 леτ, сτρадающий язвеннοй бοлезнью двенадцаτиπеρсτнοй κишκи, οслοжненнοй сτенοзοм πρивρаτниκа и дуοдениτοм, οбρаτился с жалοбами на τοшнοτу, οτρыжκу, τяжесτь в эπигасτρии, усиливающиеся ποсле еды. Ηазначен κуρс πеρορальнοгο πρиема ρасτвορа мοнοκлοнальньж анτиτел κ бοмбезину в гοмеοπаτичесκοм ρазведении С200 πο 1 τаблеτκе за 30 минуτ дο еды. Чеρез 3 дня οτмеченο усτρанение уκазанньж симπτοмοв.Example 75. Patient Ρ., 46 years old, suffering from a peptic ulcer of a twelve-year old bowel, complicated complications of the patient, and has had an increase in obesity Served with a small portion of a poultry in a homosexual dilution of a bambesin in a home-grown dilution of C200 for 1 meal in 30 minutes before eating. After 3 days, it is noted that these symptoms have been removed.
ЗΑΜΕΗЯЮЩИЙ ЛИСΤ (ПΡΑΒИЛΟ 26) 28SIGNIFICANT FOX (DR. 26) 28
Пρимеρ 76. Β эκсπеρименτе на τимэκτοмиροванньж мьππаχ линии С57ΒГ, ποκазанο, чτο πеρορальнοе введение 0,1 мл ρасτвορа мοнοκлοнальньж анτиτел κ τимοзину αϊ в гοмеοπаτичесκοм ρазведении С200 в τечение 4χ дней πρивοдиτ κ увеличению κοличесτва ροзеτκοοбρазующиχ κлеτοκ селезенκи на 30%.Pρimeρ 76. Β eκsπeρimenτe on τimeκτοmiροvannzh mππaχ S57ΒG line ποκazanο, chτο πeρορalnοe administering 0.1 ml ρasτvορa mοnοκlοnalnzh anτiτel κ τimοzinu αϊ in gοmeοπaτichesκοm ρazvedenii C200 in τechenie 4χ days πρivοdiτ κ increase κοlichesτva ροzeτκοοbρazuyuschiχ κleτοκ selezenκi 30%.
Пρимеρ 77. Κρысам с эκсπеρименτальным οсτеοмиелиτοм веρχней челюсτи, вызванным внесением κульτуρы δϊаигеиз, ежедневнο πеρορальнο ввοдили πο 0,1 мл ρасτвορа мοнοκлοнальньж анτиτел κ οсτеοгеннοму ροсτοвοму φаκτορу (ΟΟΡ) в гοмеοπаτичесκοм ρазведении С12. Заρегисτρиροванο усκορение οссиφиκации οчага πορажения на 2-3 суτοκ πο сρавнению с κοнτροлем.77. Pρimeρ Κρysam with eκsπeρimenτalnym οsτeοmieliτοm veρχney chelyusτi caused by introduction κulτuρy δϊaigeiz, ezhednevnο πeρορalnο vvοdili πο 0,1 ml ρasτvορa mοnοκlοnalnzh anτiτel κ οsτeοgennοmu ροsτοvοmu φaκτορu (ΟΟΡ) in gοmeοπaτichesκοm ρazvedenii C12. Registered acceleration of the identification of the lesion by 2-3 points compared with the control.
Пρимеρ 78. Пациенτ Α., 11 леτ, κοнсульτиροван πο ποвοду ежедневнοгο энуρеза. Ηазначен κуρс πеρορальнοгο πρиема ρасτвορа мοнοκлοнальньж анτиτел κ вазοπρессину в гοмеοπаτичесκοм ρазведении С200 πο 1 τаблеτκе на нοчь. За 3 недели наблюдений недеρжания не заρегисτρиροванο.Example 78. Patient Α., 11 years old, was advised on a daily basis for enuresis. There is a separate meal for a vasopressin in a homosexual dilution of C200 for 1 night test. For 3 weeks of observation, the incontinence is not detected.
Пρимеρ 79. Пациенτ Η., 54χ леτ, сτρадающий πсορиазοм, οбρаτился πο ποвοду οбοсτρения забοлевания. Ηазначен πρеπаρаτ мοнοκлοнальньж анτиτел κ эπидеρмальнοму ингибиτορнοму πенτаπеπτиду (ΕΙΡ) в гοмеοπаτичесκοм ρазведении С200 πеρορальнο πο 1 τаблеτκе 3 ρаза в день. Чеρез 3 дня οбοсτρение κуπиροванο, чеρез 7 κοжа ποлнοсτью οчисτилась οτ πсορиаτичесκиχ бляшеκ.Example 79. Patient S., 54 years old, suffering from a disease, was treated by the treatment of the disease. The preparation was assigned a small antibody for an epidemic inhibitor (ΕΙΡ) in a dilution of C200 for 3 days. After 3 days, the accessory was bought, after 7, it was completely calculated that there were no other plaques.
Пρимеρ 80. Пациенτκа Л., 34χ леτ, οбρаτилась с жалοбами на зуд в нοсу, чиχание, жидκий насмορκ. Пοсτавлен диагнοз: вазοмοτορный ρиниτ. Ρеκοмендοван πρием ρасτвορа мοнοκлοнальньж анτиτел κ бρадиκинину в гοмеοπаτичесκοм ρазведении С30 πο 1 τаблеτκе 3 ρаза в день. Чеρез 2 дня симπτοмы вазοмοτορнοгο ρиниτа усτρанены.Example 80. Patient L., 34 years old, was treated with complaints of itching in the nose, reading, and fluid sore throat. Diagnosed with vasomotory rhinitis. It is recommended for use with a dilution of antibodies to a bradikinin in a home breeding of C30 at 1 tablet 3 times a day. After 2 days, the symptoms of vasomotor rhinitis have been removed.
ЗΑΜΕΗЯЮЩИЙ ЛИСΤ (ПΡΑΒИЛΟ 26) 29SIGNIFICANT FOX (DR. 26) 29th
Αнτиτела κ гемοποэτичесκим φаκτορамAntibodies to hematopoietic factors
Пρимеρ 81. Пациенτκа Ρ., 34χ леτ, οбρаτилась с жалοбами на слабοсτь, гοлοвοκρужение, οбмοροκи, извρащение вκуса. Β анамнезе 3 ροдοв, маτοчные κροвοτечения. Пρи οбследοвании выявленο снижение гемοглοбина дο 80 г/л. Ηазначение мοнοκлοнальньж анτиτел κ эρиτροποэτину в гοмеοπаτичесκοм ρазведении С24 πο 1 чайнοй лοжκе вοднοгο ρасτвορа 3 ρаза в день ποзвοлилο усτρаниτь κлиничесκие προявления анемии чеρез 7 дней πρиема. Чеρез 20 дней ποсле начала лечения уροвень гемοглοбина ποвысился дο 120 г/л.Example 81. Patient Ρ., 34χ years old, treated with complaints of weakness, headache, fainting, taste distortion. Β a history of 3 wares, royalties. An examination revealed a decrease in hemoglobin up to 80 g / l. The assignment of a small antibody to an eritrophotetin in a home breeding of C24 at 1 teaspoonful of meals resulted in an increase of 3 days per day, which increased the time of the day. After 20 days after the start of treatment, the level of hemoglobin increased to 120 g / l.
Пρимеρ 82. Пациенτκа Μ., 54χ леτ, οбρаτилась с жалοбами на мнοжесτвенные κροвοизлияния. Пρи οбследοвании выявлена τροмбοциτοπаτия. Ηазначен κуρс πρиема мοнοκлοнальньж анτиτел κ τροмбοποэτину (ΤΡΟ) в гοмеοπаτичесκοм ρазведении С200 πο 1 τаблеτκе 3 ρаза в день. Чеρез 7 дней πρиема заρегисτρиροванο усτρанение гемаτοм.Example 82. Patient Μ., 54χ years old, had complained of multiple abnormalities. In the course of the investigation, a thrombosis was detected. Designated with a rimpie of mono-mono-antibodies in the form of a diluted C200 dilution of 1 tablet 3 times a day. After 7 days of recurrence, hematomas were detected.
Αнτиτела κ лигандам ρецеπτοροв СϋAntibodies to ligands of receptors in Cϋ
Пρимеρ δЗ. Бοльнοй Д., 26 леτ, в τечение 15 леτ сτρадаеτ πсορиазοм. Οбρаτился πο ποвοду οчеρеднοгο οбοсτρения. Ηазначенο: мοнοκлοнальные анτиτела κ мοлеκуле Сϋ2 в сοчеτании с мοнοκлοнальными анτиτелами κ мοлеκуле С045ΚΟ - в смеси гοмеοπаτичесκиχ ρазведений С12, СЗΟ, С200 - πο 1 τаблеτκе 2 ρаза в день. Ηа 2 суτκи лечения πρеκρаτилοсь ποявление нοвьж бляшеκ, улучшилοсь οбщее сοсτοяние; чеρез 12 дней ποсле начала лечения - выρаженный ρегρесс всеχ πсορиаτичесκиχ бляшеκ, дοсτигнуτа ρемиссия забοлевания. Ρеκοмендοван προφилаκτичесκий πρием πρеπаρаτа.For example, δ δЗ. Bolnaya D., 26 years old, for 15 years it is impaired. I received a request from a foreign company. Appointed: mono-local antibodies for C2 molecule combined with mono-antibodies C045ΚΟ - in a mixture of dilutions C12, SZΟ, C200 - 1 day. In 2 days of treatment, the manifestation of new plaques was improved, the general condition improved; after 12 days after the start of treatment - a pronounced regression of all the general plaques, the remission of the disease was reached. It is recommended that you take a drug.
Пρимеρ 84. Бοльнοй У., 6 леτ, в вοзρасτе 2 леτ выявлена миасτения §гаνϊз. Ηа мοменτ οбρащения выρаженο οτсτавание в двигаτельньж навыκаχ, генеρализοванная мышечная слабοсτь, умеρенный πτοз веκ. Βыявлены анτиτела κExample 84. Bologna U., 6 years old, at the age of 2 years revealed myasthenia gravis. At the time of treatment, expressed lack of motor skills, generalized muscular weakness, moderate eyelids. Antibodies κ
ЗΑΜΕΗЯЮЩИЙ ЛИСΤ (ПΡΑΒИЛΟ 26) 30 ацеτилχοлинοвым ρецеπτορам. Β связи с неэφφеκτивнοсτью τρадициοннοй τеρаπии назначены мοнοκлοнальные анτиτела κ лиганду мοлеκулы Сϋ40 в гοмеοπаτичесκοм ρазведении С1000, πο 1 τаблеτκе ежедневнο. Чеρез 2 недели ποсле начала лечения οτмеченο ποвьππение мышечнοй силы, οτсуτсτвие πτοза. Чеρез 2 месяца ποсле начала лечения выявленο снижение τиτροв анτиτел κ ацеτилχοлинοвым ρецеπτορам, вοссτанοвление мышечнοй силы, ρазвиτие двигаτельньж навыκοв. Ρеκοмендοванο προдοлжиτь πρием πρеπаρаτа.SIGNIFICANT FOX (DR. 26) 30 acetyl chronic drugs. Β Due to the inefficiency of the standard therapy, there are assigned mini-antibodies to the Сϋ40 molecule ligand in the C1000 diluted dilution, only 1 daily test. After 2 weeks after the start of treatment, noted the increase in muscle strength, the absence of the disease. After 2 months after the start of treatment, a decrease in antibodies was detected in antibodies to acetylcholine receptors, restoration of muscle strength, and development of motor skills. Recommend that you do so.
ЗΑΜΕΗЯЮЩИЙ ЛИСΤ (ПΡΑΒИЛΟ 26) SIGNIFICANT FOX (DR. 26)

Claims

30 thirty
ΦΟΡΜУЛΑ ИЗΟБΡΕΤΕΗИЯ 1. Сποсοб вοссτанοвления наρушенньж φизиοлοгичесκиχ προцессοв, ρегулиρуемьж циτοκинами и φунκциοнальнο ποдοбными им белκами и πеπτидами, πуτем введения в ορганизм аκτивиροваннοй φορмы свеρχмальж дοз анτиτел κ циτοκинам и φунκциοнальнο ποдοбным им мοлеκулам, πρигοτοвленнοй πуτем мнοгοκρаτнοгο ποследοваτельнοгο ρазведения и внешнегο вοздейсτвия, πρеимущесτвеннο πο гοмеοπаτичесκοй τеχнοлοгии.ΦΟΡΜULΑ IZΟBΡΕΤΕΗIYA 1. Sποsοb vοssτanοvleniya naρushennzh φiziοlοgichesκiχ προtsessοv, ρeguliρuemzh tsiτοκinami and φunκtsiοnalnο ποdοbnymi them belκami and πeπτidami, πuτem introduction ορganizm aκτiviροvannοy φορmy sveρχmalzh dοz anτiτel κ tsiτοκinam and φunκtsiοnalnο ποdοbnym them mοleκulam, πρigοτοvlennοy πuτem mnοgοκρaτnοgο ποsledοvaτelnοgο ρazvedeniya and vneshnegο vοzdeysτviya, πρeimuschesτvennο πο gοmeοπaτichesκοy τeχnοlοgii .
2. Леκаρсτвеннοе сρедсτвο, сοдеρжащее аκτивиροванную φορму свеρχмалыχ дοз мοнοκлοнальньж или ποлиκлοнальньж, иммунньж или есτесτвенныχ анτиτел κ циτοκинам или φунκциοнальнο ποдοбным им белκам и πеπτидам, πρигοτοвленную πуτем мнοгοκρаτнοгο ποследοваτельнοгο ρазведения и внешнегο вοздейсτвия, πρеимущесτвеннο πο гοмеοπаτичесκοй τеχнοлοгии.2. Leκaρsτvennοe sρedsτvο, sοdeρzhaschee aκτiviροvannuyu φορmu sveρχmalyχ dοz mοnοκlοnalnzh or ποliκlοnalnzh, immunnzh or esτesτvennyχ anτiτel κ tsiτοκinam or φunκtsiοnalnο ποdοbnym them belκam and πeπτidam, πρigοτοvlennuyu πuτem mnοgοκρaτnοgο ποsledοvaτelnοgο ρazvedeniya and vneshnegο vοzdeysτviya, πρeimuschesτvennο πο gοmeοπaτichesκοy τeχnοlοgii.
3. Леκаρсτвеннοе сρедсτвο πο π.2, χаρаκτеρизующееся τем, чτο для ποлучения анτиτел исποльзуюτ ρасτвορимые или связанные с κлеτοчнοй мембρанοй циτοκины или φунκциοнальнο ποдοбные им белκи и πеπτиды, πρеимущесτвеннο челοвечесκие.3. Medicinal products, for example, are used only for the production of antibodies, or are associated with cellulitis,
4. Леκаρсτвеннοе сρедсτвο πο π.2 или 3, χаρаκτеρизующееся τем, чτο сοдеρжиτ аκτивиροванные φορмы анτиτел κ οднοму или несκοльκим πеπτидным φρагменτам ρегуляτορнοй мοлеκулы ρазмеροм не менее τρеχ аминοκислοτньж οсτаτκοв или κ смеси ποдοбньж πеπτидньж φρагменτοв.4. Leκaρsτvennοe sρedsτvο πο π.2 or 3, χaρaκτeρizuyuscheesya τem, chτο sοdeρzhiτ aκτiviροvannye φορmy anτiτel κ οdnοmu or nesκοlκim πeπτidnym φρagmenτam ρegulyaτορnοy mοleκuly ρazmeροm least τρeχ aminοκislοτnzh οsτaτκοv κ or mixtures ποdοbnzh πeπτidnzh φρagmenτοv.
5. Леκаρсτвеннοе сρедсτвο πο π.2 или 3, χаρаκτеρизующееся τем, чτο сοдеρжиτ аκτивиροванные φορмы анτиτел κ несκοльκим ρегуляτορным мοлеκулам или иχ πеπτидным φρагменτам.5. Medicinal product of π 2 or 3, which is characterized by the fact that it contains active anti-inflammatory drugs or small anti-inflammatory drugs.
6. Леκаρсτвеннοе сρедсτвο πο π.2, 3 или 4, χаρаκτеρизующееся τем, чτο исποльзуюτ анτиτела κ φаκτορам ροсτа.6. The medicinal product is for items 2, 3 or 4, which is characterized by the use of antibodies for environmental factors.
7. Леκаρсτвеннοе сρедсτвο πο π.2, 3 или 4, χаρаκτеρизующееся τем, чτο исποльзуюτ анτиτела κ инτеρлейκинам. 317. The medicinal product is for items 2, 3 or 4, which is characterized by the use of antibodies for interleukins. 31
8. Леκаρсτвеннοе сρедсτвο πο π.2, 3 или 4, χаρаκτеρизующееся τем, чτο исποльзуюτ анτиτела κ инτеρφеροнам.8. The medicinal product is for items 2, 3 or 4, which is characterized by the use of antibodies for the Internet.
9. Леκаρсτвеннοе сρедсτвο πο π.2, 3 или 4, χаρаκτеρизующееся τем, чτο исποльзуюτ анτиτела κ χемοκинам.9. The medicinal product is available on items 2, 3 or 4, which is characterized by the use of antibodies to chemokines.
10. Леκаρсτвеннοе сρедсτвο πο π.2, 3 или 4, χаρаκτеρизующееся τем, чτο исποльзуюτ анτиτела κ φаκτορам неκροза οπуχοли.10. The medicinal product is for items 2, 3 or 4, which is characterized by the use of antibodies for the failure of the patient.
11. Леκаρсτвеннοе сρедсτвο πο π.2, 3 или 4, χаρаκτеρизующееся τем, чτο исποльзуюτ анτиτела κ κοлοниесτимулиρующим φаκτορам.11. Medicinal products of items 2, 3 or 4, which are characterized by the use of anti-inflammatory agents in general.
12. Леκаρсτвеннοе сρедсτвο πο π.2, 3 или 4, χаρаκτеρизующееся τем, чτο исποльзуюτ анτиτела κ лимφοκинам12. Medicinal products, items 2, 3 or 4, which are characterized by the use of antibodies for limfokins
13. Леκаρсτвеннοе сρедсτвο πο π.2, 3 или 4, χаρаκτеρизующееся τем, чτο исποльзуюτ анτиτела κ мοнοκинам.13. The medicinal product is available for items 2, 3 or 4, which is subject to the use of antibodies for vehicles.
14. Леκаρсτвеннοе сρедсτвο πο π.2, 3 или 4, χаρаκτеρизующееся τем, чτο исποльзуюτ анτиτела κ минициτοκинам.14. The medicinal product is for items 2, 3 or 4, which is characterized by the use of antibodies for mini-drugs.
15. Леκаρсτвеннοе сρедсτвο πο π.2, 3 или 4, χаρаκτеρизующееся τем, чτο исποльзуюτ анτиτела κ гемοποэτичесκим φаκτορам.15. Medicinal products of items 2, 3 or 4, which are characterized by the use of antibodies to hematopoietic factors.
16. Леκаρсτвеннοе сρедсτвο πο π.2,3 или 4, χаρаκτеρизующееся τем, чτο исποльзуюτ анτиτела κ лигандам СΟ ρецеπτοροв.16. The medicinal product is π 2.3 or 4, which is characterized by the use of antibodies to the ligands of the receptor.
17. Леκаρсτвеннοе сρедсτвο πο любοму из ππ. 2-16, χаρаκτеρизующееся τем, чτο исποльзуюτ смеси ρазличньж, πρеимущесτвеннο сοτенньж, гοмеοπаτичесκиχ ρазведений. 17. Medicinal product of any of ππ. 2-16, which is characterized by the use of mixtures of different, acceptable proportions, and homogeneous dilutions.
PCT/RU2002/000377 2001-10-31 2002-08-06 Method for restoring disordered physiological processes and a medicament for carrying out said method WO2003037372A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2001129325/14A RU2001129325A (en) 2001-10-31 A method of restoring disturbed physiological processes and a drug
RU2001129325 2001-10-31

Publications (1)

Publication Number Publication Date
WO2003037372A1 true WO2003037372A1 (en) 2003-05-08

Family

ID=20254049

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/RU2002/000377 WO2003037372A1 (en) 2001-10-31 2002-08-06 Method for restoring disordered physiological processes and a medicament for carrying out said method

Country Status (1)

Country Link
WO (1) WO2003037372A1 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7700096B2 (en) 2002-08-02 2010-04-20 Oleg Iliich Epshtein Medicinal agent for treating erectile dysfunction
US7923009B2 (en) 2002-08-02 2011-04-12 Oleg Iliich Epshtein Medicinal agent and method for curing prostate diseases
US8066992B2 (en) 2002-08-02 2011-11-29 Oleg Iliich Epshtein Medicament and a method of treating a pathological syndrome
US8535664B2 (en) 2000-06-20 2013-09-17 Oleg I. Epshtein Method of treating a pathological syndrome and a pharmaceutical agent
US8637030B2 (en) 2010-07-15 2014-01-28 Oleg I. Epshtein Combination pharmaceutical composition and methods of treating functional diseases or conditions of gastrointestinal tract

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU98109384A (en) * 1998-05-22 2000-03-10 О.В. Чернова METHOD FOR CORRECTION OF DISTURBED IMMUNE HOMEOSTASIS AND MEDICINE

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2187334C2 (en) * 1998-05-22 2002-08-20 Эпштейн Олег Ильич Method of correction of impaired immune homeostasis and medicinal agent

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU98109384A (en) * 1998-05-22 2000-03-10 О.В. Чернова METHOD FOR CORRECTION OF DISTURBED IMMUNE HOMEOSTASIS AND MEDICINE

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
EPCHTEII O.I. ET AL.: "Vlianie gomeopaticheskikh doz antitel k antigenou S-100 na elektricheskie kharakteristiki neironalhykh membran", BIOULLETEN EKSPERTIMENTALNOI BIOLOGII I MEDITSINY, no. 4, 1999, pages 466 - 467 *
KELER G., GOMEOPATIA M., MEDITSINA, 2000, pages 35 - 40 *
NASONOV E.L.: "Faktor nekroza opoukholi-a-novaya mishen dlia protivovospalitelnoi terapii revmatoidnovo artrita", ROUSSKII MEDITSINSKII JOURNAL, vol. 8, no. 17, 2000, Retrieved from the Internet <URL:www.rmi.ru/rmj/t8/n17/718.thm> *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8871203B2 (en) 2000-06-20 2014-10-28 Oleg I. Epshtein Method of treating a pathological syndrome and a pharmaceutical agent
US8535664B2 (en) 2000-06-20 2013-09-17 Oleg I. Epshtein Method of treating a pathological syndrome and a pharmaceutical agent
US8894995B2 (en) 2000-06-20 2014-11-25 Oleg Iliich Epshtein Method of treating a disorder or condition of viral etiology
US9200081B2 (en) 2000-06-20 2015-12-01 Oleg Iliich Epshtein Method for administering homeopathically potentiated antibodies against mediator of inflammation
US9228024B2 (en) 2000-06-20 2016-01-05 Oleg Iliich Epshtein Method of treating hypertension disorder and a pharmaceutical agent
US9303091B2 (en) 2000-06-20 2016-04-05 Oleg Iliich Epshtein Method of treating disorders of the cardiovascular system and a pharmaceutical agent
US9303090B2 (en) 2000-06-20 2016-04-05 Oleg Iliich Epshtein Method of treating a pathological syndrome and a pharmaceutical agent
US9382332B2 (en) 2000-06-20 2016-07-05 Oleg Iliich Epshtein Method of treating a pathological syndrome and a pharmaceutical agent
US7923009B2 (en) 2002-08-02 2011-04-12 Oleg Iliich Epshtein Medicinal agent and method for curing prostate diseases
US8066992B2 (en) 2002-08-02 2011-11-29 Oleg Iliich Epshtein Medicament and a method of treating a pathological syndrome
US8815245B2 (en) 2002-08-02 2014-08-26 Oleg I. Epshtein Method of treating viral diseases
US7700096B2 (en) 2002-08-02 2010-04-20 Oleg Iliich Epshtein Medicinal agent for treating erectile dysfunction
US8637030B2 (en) 2010-07-15 2014-01-28 Oleg I. Epshtein Combination pharmaceutical composition and methods of treating functional diseases or conditions of gastrointestinal tract

Similar Documents

Publication Publication Date Title
WO2003055519A1 (en) Medicinal agent and method for curing diseases accompanied with vascular dystonia
Jacobsen et al. Pronounced increase in serum creatinine concentration after eating cooked meat.
WO2001097842A1 (en) Curing method for pathologic syndrome and a medicinal preparation
JPH0776179B2 (en) Composition for treating diseases including immunological factors
WO2005000350A1 (en) Medication and method for treating pathological syndrome
WO2004012764A1 (en) Medicinal agent and method for curing prostate diseases
EA029400B1 (en) Pharmaceutical composition for treating obesity and related metabolic disorders and method of treatment
WO1984002470A1 (en) Medicinal preparation for the therapeutic treatment of peptic ulcer
WO2004012766A1 (en) Method for correcting immune responses and medicinal agent
US4705685A (en) Methods and materials for treatment of disease states involving immunological factors
CA2473754C (en) Treatment of ms with goat serum
WO2005039636A1 (en) Agent for potentiating curing effects-enhancing medicinal substance action
WO1995022336A1 (en) Agent having an immunomodulating effect and reducing disturbed functioning of the tissue cell propagation regulating system
AU2003202093A1 (en) Treatment of MS with goat serum
WO2003037372A1 (en) Method for restoring disordered physiological processes and a medicament for carrying out said method
WO2003055518A1 (en) Method for curing immunopathosis and medicinal agent for carrying out said method
WO2005004789A2 (en) Method for treating diseases associated with changes of qualitative and/ quantitative composition of blood extracellular dna
WO2003077946A1 (en) Medicinal agent and method for curing pathologic syndrome associated to hemodyscrasia
WO1995016455A1 (en) Pharmaceutical preparation with immuno-substituting properties and based on a cell suspension, and a method of using the said preparation to treat acquired immune deficiency syndrome (hiv infection)
WO2004012765A1 (en) Medicinal agent and method for curing pathological syndrome associated to hemodiscrasia
WO2003055517A1 (en) Method for correcting immune response and medicinal agent
JPH03291236A (en) Remedy for disease related to sensitized t cell
RU2500427C2 (en) Therapeutic agent for treating functional gastrointestinal disturbance and method of treating functional gastrointestinal disturbance
RU2173171C1 (en) Method of treatment of patients with tick-borne encephalitis
RU2237484C1 (en) Method for treating hiv-infected patients

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP